US5882330A
(en)
*
|
1984-05-25 |
1999-03-16 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5456663A
(en)
*
|
1984-05-25 |
1995-10-10 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
JPH0720857B2
(ja)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
リポソームおよびその製法
|
US6132763A
(en)
*
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
US20010051183A1
(en)
*
|
1989-10-20 |
2001-12-13 |
Alza Corporation |
Liposomes with enhanced circulation time and method of treatment
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5469854A
(en)
*
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US6146657A
(en)
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US5705187A
(en)
*
|
1989-12-22 |
1998-01-06 |
Imarx Pharmaceutical Corp. |
Compositions of lipids and stabilizing materials
|
US6001335A
(en)
*
|
1989-12-22 |
1999-12-14 |
Imarx Pharmaceutical Corp. |
Contrasting agents for ultrasonic imaging and methods for preparing the same
|
US6088613A
(en)
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5542935A
(en)
*
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5441746A
(en)
*
|
1989-12-22 |
1995-08-15 |
Molecular Bioquest, Inc. |
Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
|
US5352435A
(en)
*
|
1989-12-22 |
1994-10-04 |
Unger Evan C |
Ionophore containing liposomes for ultrasound imaging
|
US5580575A
(en)
*
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
US5733572A
(en)
*
|
1989-12-22 |
1998-03-31 |
Imarx Pharmaceutical Corp. |
Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
|
US5776429A
(en)
*
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5656211A
(en)
*
|
1989-12-22 |
1997-08-12 |
Imarx Pharmaceutical Corp. |
Apparatus and method for making gas-filled vesicles of optimal size
|
US5922304A
(en)
*
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
US20060084797A1
(en)
*
|
1990-06-11 |
2006-04-20 |
Gilead Sciences, Inc. |
High affinity TGFbeta nucleic acid ligands and inhibitors
|
US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20030113369A1
(en)
*
|
1991-01-16 |
2003-06-19 |
Martin Francis J. |
Liposomes with enhanced circulation time and method of treatment
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
US5874062A
(en)
*
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
JP3220180B2
(ja)
*
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
GB9111611D0
(en)
*
|
1991-05-30 |
1991-07-24 |
Sandoz Ltd |
Liposomes
|
EP1236473A3
(de)
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Selbst zusammenbaubares system zur verabreichung von polynukleotiden
|
ZA933926B
(en)
*
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
JP3337075B2
(ja)
*
|
1992-08-05 |
2002-10-21 |
名糖産業株式会社 |
小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
|
NL9201722A
(nl)
*
|
1992-10-05 |
1994-05-02 |
Stichting Tech Wetenschapp |
Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US6764693B1
(en)
*
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
JP3351476B2
(ja)
*
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
US5395619A
(en)
*
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
US6326353B1
(en)
*
|
1993-03-23 |
2001-12-04 |
Sequus Pharmaceuticals, Inc. |
Enhanced circulation effector composition and method
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
AU6368394A
(en)
*
|
1993-03-23 |
1994-10-11 |
Liposome Technology, Inc. |
Polymer-polypeptide composition and method
|
WO1994026251A1
(en)
*
|
1993-05-07 |
1994-11-24 |
Sequus Pharmaceuticals, Inc. |
Subcutaneous liposome delivery method
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
US20050181976A1
(en)
*
|
1993-05-10 |
2005-08-18 |
Ekwuribe Nnochiri N. |
Amphiphilic oligomers
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
WO1994027580A1
(en)
*
|
1993-05-21 |
1994-12-08 |
The Liposome Company, Inc. |
Reduction of liposome-induced adverse physiological reactions
|
US5514670A
(en)
*
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
JP4076026B2
(ja)
*
|
1993-10-25 |
2008-04-16 |
トランセイヴ,インコーポレイテッド |
リポソームディフェンシン
|
US5415869A
(en)
*
|
1993-11-12 |
1995-05-16 |
The Research Foundation Of State University Of New York |
Taxol formulation
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
US7083572B2
(en)
*
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
WO1995016464A1
(en)
*
|
1993-12-14 |
1995-06-22 |
Johns Hopkins University School Of Medicine |
Controlled release of pharmaceutically active substances for immunotherapy
|
US6773719B2
(en)
|
1994-03-04 |
2004-08-10 |
Esperion Luv Development, Inc. |
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
|
US6312719B1
(en)
*
|
1994-03-04 |
2001-11-06 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
US20010055581A1
(en)
*
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US5736121A
(en)
*
|
1994-05-23 |
1998-04-07 |
Imarx Pharmaceutical Corp. |
Stabilized homogenous suspensions as computed tomography contrast agents
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US5785992A
(en)
*
|
1994-09-30 |
1998-07-28 |
Inex Pharmaceuticals Corp. |
Compositions for the introduction of polyanionic materials into cells
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
CN1080575C
(zh)
*
|
1994-10-14 |
2002-03-13 |
蛋白质传送股份有限公司 |
结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
|
ATE198419T1
(de)
*
|
1994-10-14 |
2001-01-15 |
Liposome Co Inc |
Etherlipid-liposomen und deren therapeutische verwendung
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
US5827531A
(en)
*
|
1994-12-02 |
1998-10-27 |
The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration |
Microcapsules and methods for making
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
US5658588A
(en)
*
|
1995-03-31 |
1997-08-19 |
University Of Cincinnati |
Fibrinogen-coated liposomes
|
GB9509016D0
(en)
*
|
1995-05-03 |
1995-06-21 |
Royal Free Hosp School Med |
Tissue entrapment
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5997898A
(en)
*
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
US6139819A
(en)
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
WO1996040964A2
(en)
*
|
1995-06-07 |
1996-12-19 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6521211B1
(en)
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
HUP9802445A3
(en)
*
|
1995-08-01 |
1999-03-29 |
Novartis Ag |
Liposomal oligonucleotide compositions and process for inhibiting the human raf
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
US5858397A
(en)
*
|
1995-10-11 |
1999-01-12 |
University Of British Columbia |
Liposomal formulations of mitoxantrone
|
CA2231547A1
(en)
*
|
1995-10-11 |
1997-04-17 |
Kevin Jon Williams |
Liposomal compositions and methods of using them
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US5626654A
(en)
|
1995-12-05 |
1997-05-06 |
Xerox Corporation |
Ink compositions containing liposomes
|
US5817856A
(en)
*
|
1995-12-11 |
1998-10-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiation-protective phospholipid and method
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
EP1619250B1
(de)
|
1996-01-08 |
2009-11-25 |
Genentech, Inc. |
OB Rezeptor-Variante und Liganden
|
US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US5965159A
(en)
*
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US6197333B1
(en)
|
1996-03-28 |
2001-03-06 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved liposome compositions
|
ATE345682T1
(de)
|
1996-05-01 |
2006-12-15 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2005121368A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5919480A
(en)
|
1996-06-24 |
1999-07-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal influenza vaccine composition and method
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
WO1998007409A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Sequus Pharmaceuticals, Inc. |
Liposomes containing a cisplatin compound
|
AU729077B2
(en)
*
|
1996-08-26 |
2001-01-25 |
Transgene S.A. |
Cationic lipid-nucleic acid complexes
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
ES2289188T3
(es)
*
|
1996-09-11 |
2008-02-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
|
US5846517A
(en)
*
|
1996-09-11 |
1998-12-08 |
Imarx Pharmaceutical Corp. |
Methods for diagnostic imaging using a renal contrast agent and a vasodilator
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
EP0932390A1
(de)
*
|
1996-10-11 |
1999-08-04 |
Sequus Pharmaceuticals, Inc. |
Therapeutische liposomenzusammensetzung und verfahren
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
US6056973A
(en)
*
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
US6339069B1
(en)
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
DK0964690T3
(da)
*
|
1996-10-15 |
2003-10-20 |
Liposome Co Inc |
Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration
|
US6331289B1
(en)
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US20070036722A1
(en)
*
|
1996-10-28 |
2007-02-15 |
Pal Rongved |
Separation processes
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
CZ149499A3
(cs)
*
|
1996-10-28 |
1999-09-15 |
Nycomed Imaging As |
Diagnostický a/nebo léčebný prostředek
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
AU6161898A
(en)
*
|
1997-02-14 |
1998-09-08 |
Regents Of The University Of California, The |
Lamellar gels and methods for making and regulating
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US6090800A
(en)
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
US6143276A
(en)
*
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
IL132120A0
(en)
|
1997-04-03 |
2001-03-19 |
Guilford Pharm Inc |
Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
|
KR100794454B1
(ko)
|
1997-04-07 |
2008-01-16 |
제넨테크, 인크. |
항-vegf 항체
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
WO1998044910A1
(en)
|
1997-04-09 |
1998-10-15 |
Philipp Lang |
NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO)
|
US20020039594A1
(en)
*
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
EP1027033B1
(de)
*
|
1997-05-14 |
2009-07-22 |
The University Of British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
DE19724796A1
(de)
*
|
1997-06-06 |
1998-12-10 |
Max Delbrueck Centrum |
Mittel zur Antitumortherapie
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
AU735588B2
(en)
|
1997-09-18 |
2001-07-12 |
Pacira Pharmaceuticals, Inc. |
Sustained-release liposomal anesthetic compositions
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
ES2384094T3
(es)
|
1997-11-14 |
2012-06-29 |
Pacira Pharmaceuticals, Inc. |
Producción de liposomas multivesiculares
|
EP2014677A1
(de)
|
1997-11-21 |
2009-01-14 |
Genentech, Inc. |
Mit A33 vewandte Antigene und deren pharmazeutische Verwendung
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
US6787132B1
(en)
*
|
1997-12-04 |
2004-09-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combined chemo-immunotherapy with liposomal drugs and cytokines
|
ATE442128T1
(de)
*
|
1997-12-04 |
2009-09-15 |
Yissum Res Dev Co |
Kombinierte chemo-immunotherapie mit liposomalen arzneistoffen und cytokinen
|
EP1947119A3
(de)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
|
US6123923A
(en)
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
JP4485051B2
(ja)
|
1998-02-04 |
2010-06-16 |
ジェネンテック, インコーポレイテッド |
上皮細胞増殖因子としてのヘレグリンの用途
|
NZ506051A
(en)
*
|
1998-02-09 |
2003-08-29 |
Bracco Res S |
Targeted delivery of biologically active media
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
ES2389387T3
(es)
|
1998-03-17 |
2012-10-25 |
Genentech, Inc. |
Polipéptidos homólogos de VEGF y de BMP1
|
WO1999048495A1
(en)
*
|
1998-03-25 |
1999-09-30 |
Biosource Technologies, Inc. |
Benzoates derivatives for inhibiting angiogenesis
|
US6433012B1
(en)
*
|
1998-03-25 |
2002-08-13 |
Large Scale Biology Corp. |
Method for inhibiting inflammatory disease
|
US6858706B2
(en)
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
CA2329768C
(en)
*
|
1998-04-27 |
2008-06-10 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising factor viii and neutral liposomes
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6169078B1
(en)
*
|
1998-05-12 |
2001-01-02 |
University Of Florida |
Materials and methods for the intracellular delivery of substances
|
EP2333069A3
(de)
|
1998-05-15 |
2011-09-14 |
Genentech, Inc. |
Therapeutische verwendungen von il-17 homologe polypeptide
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
EP1865061A3
(de)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
ES2395693T3
(es)
|
1998-06-12 |
2013-02-14 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
|
US6726925B1
(en)
*
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
AU752225B2
(en)
|
1998-07-17 |
2002-09-12 |
Pacira Pharmaceuticals, Inc. |
Biodegradable compositions for the controlled release of encapsulated substances
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6703381B1
(en)
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
DE69907243T2
(de)
*
|
1998-09-16 |
2004-02-19 |
Alza Corp., Mountain View |
In liposomen eingeschlossene topoisomerase inhibitoren
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6153212A
(en)
|
1998-10-02 |
2000-11-28 |
Guilford Pharmaceuticals Inc. |
Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
|
US6419709B1
(en)
|
1998-10-02 |
2002-07-16 |
Guilford Pharmaceuticals, Inc. |
Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
DE69934425T2
(de)
*
|
1998-10-23 |
2007-09-27 |
Amgen Inc., Thousand Oaks |
Thrombopoietin substitute
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
CA2350599A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6773911B1
(en)
*
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
ATE300957T1
(de)
|
1998-12-22 |
2005-08-15 |
Genentech Inc |
Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
|
EP2075335A3
(de)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
|
US6350464B1
(en)
|
1999-01-11 |
2002-02-26 |
Guilford Pharmaceuticals, Inc. |
Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
|
US6818227B1
(en)
*
|
1999-02-08 |
2004-11-16 |
Alza Corporation |
Liposome composition and method for administration of a radiosensitizer
|
US6537585B1
(en)
|
1999-03-26 |
2003-03-25 |
Guilford Pharmaceuticals, Inc. |
Methods and compositions for treating solid tumors
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
EP1176962B1
(de)
*
|
1999-04-29 |
2004-02-11 |
Alza Corporation |
Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
|
CA2270600A1
(en)
|
1999-05-03 |
2000-11-03 |
Infectio Recherche Inc. |
Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
|
EP1645292A1
(de)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
|
AU4430200A
(en)
*
|
1999-05-11 |
2000-11-21 |
Sankyo Company Limited |
Liposome preparation of fat-soluble antitumor drug
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6309633B1
(en)
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
EP1190705A4
(de)
*
|
1999-06-24 |
2009-03-18 |
Kyowa Hakko Kogyo Kk |
Verfahren zur regulation des herausdiffundierens von in liposomen verkapseltem arzneistoff
|
HU226742B1
(en)
|
1999-06-25 |
2009-08-28 |
Genentech Inc |
Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
NZ517150A
(en)
|
1999-08-27 |
2005-01-28 |
Genentech Inc |
Dosages for treatment with anti-ErbB2 antibodies
|
KR100510795B1
(en)
*
|
1999-08-31 |
2005-08-30 |
|
Compositions and Methods for the Treatment of Tumor
|
KR20010085996A
(ko)
*
|
1999-09-03 |
2001-09-07 |
스티븐 엠. 오드레 |
암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
|
WO2001026625A2
(en)
*
|
1999-10-08 |
2001-04-19 |
Alza Corp |
Neutral-cationic lipid for nucleic acid and drug delivery
|
IT1315253B1
(it)
*
|
1999-10-22 |
2003-02-03 |
Novuspharma Spa |
Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US6511676B1
(en)
*
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
CA2392477A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
CA2490853A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6593308B2
(en)
|
1999-12-03 |
2003-07-15 |
The Regents Of The University Of California |
Targeted drug delivery with a hyaluronan ligand
|
CA2393595A1
(en)
*
|
1999-12-10 |
2001-06-14 |
Gigi Chiu |
Lipid carrier compositions with protected surface reactive functions
|
DK1897945T3
(da)
|
1999-12-23 |
2012-05-07 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
WO2001049268A1
(en)
*
|
2000-01-05 |
2001-07-12 |
Imarx Therapeutics, Inc. |
Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
|
ATE424457T1
(de)
*
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
CA2398514A1
(en)
*
|
2000-01-28 |
2001-08-02 |
Robert M. Abra |
Liposomes containing an entrapped compound in supersaturated solution
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
JP4922824B2
(ja)
*
|
2000-04-03 |
2012-04-25 |
参天製薬株式会社 |
送達性物質およびそれを利用した薬物デリバリーシステム
|
LT2857516T
(lt)
|
2000-04-11 |
2017-09-11 |
Genentech, Inc. |
Multivalentiniai antikūnai ir jų panaudojimas
|
ATE382333T1
(de)
*
|
2000-04-12 |
2008-01-15 |
Liplasome Pharma As |
Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
|
PT1290013E
(pt)
|
2000-04-21 |
2006-06-30 |
Amgen Inc |
Derivados dos peptidos apo-ai/aii
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
AU2001258106A1
(en)
*
|
2000-05-11 |
2001-11-20 |
Celator Technologies Inc. |
Lipid carrier compositions for improved drug retention
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
AU6531101A
(en)
|
2000-06-02 |
2001-12-17 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1286704T3
(da)
|
2000-06-02 |
2014-09-22 |
Univ Texas |
Ethylendicystein (EC)-glucose analoge konjugater
|
US20030072794A1
(en)
*
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
EP1299128A2
(de)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
DK2042597T3
(da)
|
2000-06-23 |
2014-08-11 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
WO2002044342A2
(en)
|
2000-10-18 |
2002-06-06 |
The Brigham And Women's Hospital, Inc. |
Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
WO2002036073A2
(en)
*
|
2000-11-02 |
2002-05-10 |
Smithkline Beecham Corporation |
Receptor antagonist-lipid conjugates and delivery vehicles containing same
|
DE10056136A1
(de)
*
|
2000-11-07 |
2002-05-16 |
Nemod New Modalities |
Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
|
WO2002043665A2
(en)
*
|
2000-11-30 |
2002-06-06 |
The Research Foundation Of State University Of New York |
Ahf associated dispersion system and method for preparation
|
US8110218B2
(en)
*
|
2000-11-30 |
2012-02-07 |
The Research Foundation Of State University Of New York |
Compositions and methods for less immunogenic protein-lipid complexes
|
US7625584B2
(en)
*
|
2000-11-30 |
2009-12-01 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
WO2002061036A2
(en)
*
|
2000-11-30 |
2002-08-08 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
US20060014674A1
(en)
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
EP1908770B2
(de)
*
|
2000-12-18 |
2015-07-15 |
Cubist Pharmaceuticals, Inc. |
Verfahren zur Herstellung gereinigter Lipopeptide
|
WO2002059145A1
(en)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified lipopeptides
|
US20040077604A1
(en)
|
2001-12-19 |
2004-04-22 |
Lenard Lichtenberger |
Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
AR035779A1
(es)
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
US20020197210A1
(en)
*
|
2001-03-08 |
2002-12-26 |
Bednarski Mark David |
Stabilized therapeutic and imaging agents
|
HUP0303616A3
(en)
*
|
2001-03-26 |
2006-07-28 |
Alza Corp Mountain View |
Liposome composition for improved intracellular delivery of a therapeutic agent
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
CA2445947A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
WO2002087541A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
PT1385882E
(pt)
|
2001-05-11 |
2008-01-11 |
Amgen Inc |
Péptidos e moléculas relacionadas que se ligam a tall- 1
|
US20050261214A1
(en)
*
|
2001-05-15 |
2005-11-24 |
Serge Braun |
Complexes for transferring substances of interest into a cell
|
US20030138429A1
(en)
*
|
2001-05-22 |
2003-07-24 |
Pizzo Salvatore V. |
Compositions and methods for inhibiting metastasis
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
CA2448956C
(en)
|
2001-05-30 |
2017-10-03 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
EP1395243A2
(de)
*
|
2001-05-31 |
2004-03-10 |
SkyePharma Inc. |
Verkapselung von nanosuspensionen in liposomen und mikrosphärulen
|
US6713452B2
(en)
*
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US20060270003A1
(en)
|
2003-07-08 |
2006-11-30 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
AU2002312410A1
(en)
*
|
2001-06-08 |
2002-12-23 |
Target Protein Technologies, Inc. |
Tissue-specific endothelial membrane proteins
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CN1827766B
(zh)
|
2001-06-28 |
2010-08-25 |
徐荣祥 |
体外细胞的培养方法
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
WO2003007915A2
(en)
*
|
2001-07-19 |
2003-01-30 |
Guilford Pharmaceuticals, Inc. |
Compositions for treatment of head and neck cancers, and methods of making and using the same
|
AU2002354957A1
(en)
*
|
2001-07-19 |
2003-03-03 |
Guilford Pharmaceuticals, Inc. |
Biocompatible polymer containing composition for treatment of prostate cancers
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
IL160016A0
(en)
*
|
2001-07-29 |
2004-06-20 |
Yissum Res Dev Co |
Osteogenic growth oligopeptides as stimulants of hematopoiesis
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
AU2002323266B2
(en)
*
|
2001-08-20 |
2008-04-24 |
Transave, Inc. |
Method for treating lung cancers
|
ES2429132T3
(es)
|
2001-08-31 |
2013-11-13 |
The Rockefeller University |
Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7547673B2
(en)
*
|
2001-09-13 |
2009-06-16 |
The Johns Hopkins University |
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
KR20040063901A
(ko)
*
|
2001-09-28 |
2004-07-14 |
에스페리온 테라피유틱스 인코포레이티드 |
고압에서 소포체를 압출하는 방법 및 장치
|
DE10148065A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
(Ester)-Lysolecithine in Liposomen
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
IL161733A0
(en)
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
JP2005516897A
(ja)
*
|
2001-11-07 |
2005-06-09 |
イネックス ファーマシューティカルズ コーポレイション |
改善された粘膜のワクチン及びその使用方法
|
US20040219201A1
(en)
*
|
2001-12-06 |
2004-11-04 |
Yechezkel Barenholz |
Tempamine compositions and methods of use
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
EP1469810A4
(de)
|
2002-01-04 |
2009-01-14 |
Univ Rockefeller |
Zusammensetzungen und verfahren zur verhütung und behandlung von erkrankungen im zusammenhang mit amyloid-beta peptid
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
JP4304077B2
(ja)
*
|
2002-02-13 |
2009-07-29 |
イミュノロジー ラボラトリーズ インコーポレイテッド |
微生物感染の処置のための組成物および方法
|
EP1575480A4
(de)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
|
US20070122406A1
(en)
|
2005-07-08 |
2007-05-31 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2483476A1
(en)
*
|
2002-04-22 |
2003-10-30 |
Absorber, Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
WO2003105768A2
(en)
*
|
2002-06-13 |
2003-12-24 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
DK1519714T3
(da)
|
2002-06-28 |
2011-01-31 |
Protiva Biotherapeutics Inc |
Fremgangsmåde og apparat til fremstilling af liposomer
|
US7718160B2
(en)
*
|
2002-07-02 |
2010-05-18 |
The Board Of Regents Of The University Of Texas System |
Radiolabeled compounds and liposomes and their method of making and using same
|
US20040247661A1
(en)
*
|
2002-07-03 |
2004-12-09 |
Dov Michaeli |
Liposomal vaccine
|
US20050169979A1
(en)
*
|
2002-07-03 |
2005-08-04 |
Dov Michaeli |
Liposomal vaccine
|
CA2489919A1
(en)
*
|
2002-07-03 |
2004-01-15 |
Aphton Corporation |
Liposomal vaccine
|
CA2489588A1
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7622118B2
(en)
*
|
2002-07-15 |
2009-11-24 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected antibodies to aminophospholipids
|
CN104001181B
(zh)
*
|
2002-07-15 |
2017-05-10 |
得克萨斯大学体系董事会 |
与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗和诊断用途
|
US7625563B2
(en)
*
|
2002-07-15 |
2009-12-01 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
|
US7572448B2
(en)
*
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Combined cancer treatment methods using selected antibodies to aminophospholipids
|
US7615223B2
(en)
*
|
2002-07-15 |
2009-11-10 |
Board Of Regents, The University Of Texas System |
Selected immunoconjugates for binding to aminophospholipids
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
US7714109B2
(en)
*
|
2002-07-15 |
2010-05-11 |
Board Of Regents, The University Of Texas System |
Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
|
US7678386B2
(en)
*
|
2002-07-15 |
2010-03-16 |
Board Of Regents The University Of Texas |
Liposomes coated with selected antibodies that bind to aminophospholipids
|
WO2004007693A2
(en)
*
|
2002-07-16 |
2004-01-22 |
University Of South Florida |
Human immunosuppressive protein
|
US20040161423A1
(en)
*
|
2002-07-18 |
2004-08-19 |
Sanjeev Kumar (Mendiratta) |
Polymer modified anti-angiogenic serpins
|
WO2004054499A2
(en)
*
|
2002-08-02 |
2004-07-01 |
Transave, Inc. |
Platinum aggregates and process for producing the same
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
EP1393720A1
(de)
*
|
2002-08-27 |
2004-03-03 |
Universiteit Utrecht |
Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
|
JP2006508056A
(ja)
|
2002-08-28 |
2006-03-09 |
イミュネックス・コーポレーション |
心臓血管疾患を治療するための組成物および方法
|
AR036316A1
(es)
*
|
2002-08-29 |
2004-08-25 |
Monte Verde S A |
Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
|
US20070231379A1
(en)
*
|
2002-08-29 |
2007-10-04 |
Slater James L |
Liposome-entrapped topoisomerase inhibitors
|
US7655772B2
(en)
|
2002-09-06 |
2010-02-02 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP2277532A1
(de)
|
2002-09-11 |
2011-01-26 |
Genentech, Inc. |
Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
|
CN1694959B
(zh)
*
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
CA2498274A1
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
EP1585482A4
(de)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
Neue zusammensetzungen und verfahren zur behandlung von psoriasis
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
CN1705491B
(zh)
|
2002-09-27 |
2013-05-29 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
AU2003284010A1
(en)
*
|
2002-10-04 |
2004-05-04 |
Rinat Neuroscience Corp. |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
PL211654B1
(pl)
|
2002-10-08 |
2012-06-29 |
Rinat Neuroscience Corp |
Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
JP2006519762A
(ja)
*
|
2002-10-09 |
2006-08-31 |
ライナット ニューロサイエンス コーポレイション |
アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
|
WO2004039956A2
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004110345A2
(en)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2004044132A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
JP2006516094A
(ja)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
ナチュラルキラー細胞関連疾患の治療のための組成物と方法
|
US20040093198A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Carbon Design Systems |
Hardware simulation with access restrictions
|
AU2003285200A1
(en)
*
|
2002-11-09 |
2004-06-03 |
Nobex Corporation |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
EP1569695B1
(de)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense-modulation von apolipoprotein-b-expression
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
US20050158375A1
(en)
*
|
2002-11-15 |
2005-07-21 |
Toshikiro Kimura |
Pharmaceutical composition containing liposomes for treating cancer
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
CA2504287A1
(en)
|
2002-11-26 |
2004-06-10 |
Nobex Corporation |
Natriuretic compounds, conjugates, and uses thereof
|
EP2308968A1
(de)
|
2002-11-26 |
2011-04-13 |
Genentech, Inc. |
Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US7491699B2
(en)
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
US20040219204A1
(en)
*
|
2002-12-19 |
2004-11-04 |
Huang Ken Shi Kun |
Method of treating angiogenic tissue growth
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
NZ587852A
(en)
|
2002-12-24 |
2012-02-24 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
JP5355842B2
(ja)
|
2002-12-31 |
2013-11-27 |
ザイダス ビーエスヴィ ファーマ プライベート リミテッド |
非ペギレート化長循環性リポソーム
|
EP2058275A1
(de)
*
|
2003-01-07 |
2009-05-13 |
Ramot at Tel-Aviv University Ltd. |
Peptidnanostrukturen mit einem verkapselten Fremdstoff und Verfahren zu ihrer Herstellung
|
EP1591450A4
(de)
*
|
2003-01-10 |
2006-05-17 |
Yamanouchi Pharma Co Ltd |
Konjugat für retention im blut und krebsgewebespezifische wirkstofffreisetzung
|
US7169892B2
(en)
|
2003-01-10 |
2007-01-30 |
Astellas Pharma Inc. |
Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
|
DK1597366T3
(da)
|
2003-02-11 |
2013-02-25 |
Antisense Therapeutics Ltd |
Modulering af ekspression af insulin-lignende vækstfaktor receptor I
|
AU2004213044A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20060198882A1
(en)
*
|
2003-03-21 |
2006-09-07 |
Yechezkel Barenholz |
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
|
CA2520864A1
(en)
|
2003-03-31 |
2004-10-21 |
Alza Corporation |
Lipid particles having asymmetric lipid coating and method of preparing same
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
RS51686B
(sr)
|
2003-04-09 |
2011-10-31 |
Genentech Inc. |
Lečenje autoimune bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
EP1633440B1
(de)
*
|
2003-04-15 |
2008-05-14 |
Opperbas Holding B.V. |
Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
EP1620112A4
(de)
*
|
2003-04-17 |
2007-04-25 |
Univ Columbia |
Desmoglein 4 ist ein neues gen, das am haarwachstum beteiligt ist
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
NZ543934A
(en)
|
2003-05-12 |
2008-06-30 |
Affymax Inc |
Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
|
US20050107297A1
(en)
|
2003-05-12 |
2005-05-19 |
Holmes Christopher P. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
AU2004253455B2
(en)
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
JP2007526219A
(ja)
*
|
2003-06-04 |
2007-09-13 |
カンジ,インコーポレイテッド |
トランスフェクション薬剤
|
EP1636593B9
(de)
|
2003-06-06 |
2009-12-16 |
Genentech, Inc. |
Modulation der wechselwirkung zwischen hgf-beta-kette und c-met
|
EP1636266A2
(de)
|
2003-06-11 |
2006-03-22 |
Wyeth a Corporation of the State of Delaware |
Fusionspolypeptide des platelet glycoprotein ib alpha variant und verfahren zu deren anwendung
|
WO2005007812A2
(en)
|
2003-07-03 |
2005-01-27 |
University Of Medicine And Dentistry Of New Jersey |
Genes as diagnostic tools for autism
|
US7939058B2
(en)
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
AU2004257373B2
(en)
*
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
CN100431525C
(zh)
*
|
2003-07-17 |
2008-11-12 |
台湾东洋药品工业股份有限公司 |
脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
WO2005011600A2
(en)
*
|
2003-07-31 |
2005-02-10 |
The Board Of Regents Of The University Of Texas System |
Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
WO2005016349A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methods of inhibiting leukocyte accumulation
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
ES2321841T3
(es)
*
|
2003-08-26 |
2009-06-12 |
Smithkline Beecham Corporation |
Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones.
|
US8986731B2
(en)
*
|
2003-08-26 |
2015-03-24 |
Biolitec Pharma Marketing Ltd |
Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
|
US8846079B1
(en)
|
2004-12-01 |
2014-09-30 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
US20060115523A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Konduri Kameswari S |
Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
|
US11324698B2
(en)
|
2003-08-28 |
2022-05-10 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
JP4804923B2
(ja)
*
|
2003-09-03 |
2011-11-02 |
協和発酵キリン株式会社 |
グリセロール誘導体で修飾された化合物
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
NZ592917A
(en)
*
|
2003-09-15 |
2012-12-21 |
Protiva Biotherapeutics Inc |
Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
|
AR045937A1
(es)
|
2003-09-18 |
2005-11-16 |
Lilly Co Eli |
Modulacion de la expresion del factor de iniciacion eucariotico eif4e
|
EP1663199B1
(de)
*
|
2003-09-25 |
2013-04-03 |
Tel Aviv University Future Technology Development L.P. |
Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US7625707B2
(en)
*
|
2003-10-02 |
2009-12-01 |
Ramot At Tel Aviv University Ltd. |
Antibacterial agents and methods of identifying and utilizing same
|
JP2007507430A
(ja)
|
2003-10-10 |
2007-03-29 |
メディテック リサーチ リミテッド |
疾患の治療におけるヒアルロナン合成および分解の調節法
|
CA2542099A1
(en)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
WO2005041870A2
(en)
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
AU2004283758A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Alza Corporation |
Preparation of lipid particles
|
WO2005040163A1
(en)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP1686959B1
(de)
*
|
2003-11-14 |
2009-06-24 |
HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute) |
Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
|
US20050129753A1
(en)
*
|
2003-11-14 |
2005-06-16 |
Gabizon Alberto A. |
Method for drug loading in liposomes
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
WO2005060520A2
(en)
*
|
2003-11-25 |
2005-07-07 |
Dana-Farber Cancer Institute, Inc. |
ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
KR101195291B1
(ko)
|
2003-12-11 |
2012-10-26 |
제넨테크, 인크. |
C-met 이량체화 및 활성화를 억제하는 방법 및조성물
|
CA2551097A1
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
CA2553426A1
(en)
*
|
2004-01-15 |
2005-08-04 |
Alza Corporation |
Liposome composition for delivery of therapeutic agents
|
EP1711606A2
(de)
|
2004-01-20 |
2006-10-18 |
Isis Pharmaceuticals, Inc. |
Modulation der expression des glucocorticoidrezeptors
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
CA2559853A1
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
DK1716181T3
(da)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR-reparerede antistoffer
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
EP1579850A3
(de)
*
|
2004-03-15 |
2009-12-16 |
Nipro Corporation |
Pharmazeutische Zubereitung mit Lipsomen zur Behandlung von Krebs
|
EP2700720A3
(de)
|
2004-03-15 |
2015-01-28 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
|
AU2005223654A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
ES2707393T3
(es)
*
|
2004-03-26 |
2019-04-03 |
Curis Inc |
Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos
|
WO2005092388A1
(ja)
*
|
2004-03-26 |
2005-10-06 |
Terumo Kabushiki Kaisha |
リポソーム製剤
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
JP5301152B2
(ja)
|
2004-04-07 |
2013-09-25 |
ライナット ニューロサイエンス コーポレイション |
神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
|
US20060002930A1
(en)
*
|
2004-04-16 |
2006-01-05 |
Genentech, Inc. |
Treatment of disorders
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
EP3173073A1
(de)
|
2004-05-03 |
2017-05-31 |
Merrimack Pharmaceuticals, Inc. |
Liposome zur arzneimittelverabreichung
|
US8658203B2
(en)
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
EP3943494A1
(de)
*
|
2004-05-13 |
2022-01-26 |
Icos Corporation |
Chinazolinone als inhibitoren von humanem phosphatidylinosit-3-kinase-delta
|
ATE450251T1
(de)
*
|
2004-05-17 |
2009-12-15 |
Tekmira Pharmaceuticals Corp |
Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
|
US20060292554A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Genentech, Inc. |
Major coat protein variants for C-terminal and bi-terminal display
|
US20050260260A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Edward Kisak |
Liposome compositions for the delivery of macromolecules
|
CN101001633A
(zh)
*
|
2004-05-21 |
2007-07-18 |
特兰萨夫公司 |
肺病和肺病前期病症的治疗
|
WO2005115383A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Substituted triazoles as modulators of ppar and methods of their preparation
|
WO2005115384A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
|
JP2008500338A
(ja)
*
|
2004-05-25 |
2008-01-10 |
イコス・コーポレイション |
造血細胞の異常増殖を治療及び/又は予防する方法
|
ES2623362T3
(es)
*
|
2004-05-28 |
2017-07-11 |
Human Biomolecular Research Institute |
Analgésicos metabólicamente estables y medicaciones para el dolor
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2005252663B2
(en)
*
|
2004-06-03 |
2011-07-07 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
TW201422238A
(zh)
|
2004-06-04 |
2014-06-16 |
Genentech Inc |
Cd20抗體於治療多發性硬化症之用途及用於該用途之物品
|
AU2005251403B2
(en)
|
2004-06-07 |
2011-09-01 |
Arbutus Biopharma Corporation |
Cationic lipids and methods of use
|
CA2569664C
(en)
*
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
WO2006025920A2
(en)
*
|
2004-06-19 |
2006-03-09 |
Human Biomolecular Research Institute |
Modulators of central nervous system neurotransmitters
|
CA2571243A1
(en)
|
2004-06-21 |
2006-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
US20060019893A1
(en)
*
|
2004-07-02 |
2006-01-26 |
Genentech, Inc. |
Factor VIIa variants
|
CA2572439A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
CA2572765C
(en)
*
|
2004-07-08 |
2013-05-21 |
Amgen Inc. |
Compound having improved bioefficiency when administered in a multidose regimen
|
US20090156471A1
(en)
*
|
2004-07-15 |
2009-06-18 |
Ramot At Tel Aviv University Ltd. |
Use of anti-amyloid agents for treating and typing pathogen infections
|
AU2005272993B2
(en)
|
2004-07-15 |
2010-02-11 |
Xencor, Inc |
Optimized Fc variants
|
US7875700B2
(en)
|
2004-07-19 |
2011-01-25 |
Biocon Limited |
Cation complexes of insulin compound conjugates, formulation and uses thereof
|
US20060051405A1
(en)
*
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
ES2339789T3
(es)
|
2004-07-20 |
2010-05-25 |
Genentech, Inc. |
Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
|
ES2532610T3
(es)
|
2004-07-26 |
2015-03-30 |
Genentech, Inc. |
Procedimientos y composiciones para modular la activación del factor de crecimiento de hepatocitos
|
EA016357B1
(ru)
*
|
2004-07-30 |
2012-04-30 |
Ринат Ньюросайенс Корп. |
Антитела, направленные против бета-амилоидного пептида, и способы их применения
|
EP1781310B1
(de)
*
|
2004-08-02 |
2015-10-14 |
Ramot at Tel Aviv University Ltd. |
Artikel von peptidnanostrukturen und herstellungsverfahren dafür
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
JP4934036B2
(ja)
|
2004-08-17 |
2012-05-16 |
タイコ ヘルスケア グループ リミテッド パートナーシップ |
抗癒着着バリア
|
JP2006056807A
(ja)
*
|
2004-08-18 |
2006-03-02 |
Konica Minolta Medical & Graphic Inc |
光線力学療法製剤
|
US7732479B2
(en)
|
2004-08-19 |
2010-06-08 |
Tel Aviv University Future Technology Development L.P. |
Compositions for treating amyloid associated diseases
|
JP4715133B2
(ja)
*
|
2004-08-26 |
2011-07-06 |
コニカミノルタエムジー株式会社 |
抗腫瘍リポソーム製剤およびその製造方法
|
JP2006069929A
(ja)
*
|
2004-08-31 |
2006-03-16 |
Konica Minolta Medical & Graphic Inc |
真菌症治療製剤およびその製造方法
|
US7786086B2
(en)
*
|
2004-09-08 |
2010-08-31 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006027787A1
(en)
*
|
2004-09-09 |
2006-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal compositions of glucocorticoid and glucocorticoid derivatives
|
JP2008512444A
(ja)
*
|
2004-09-09 |
2008-04-24 |
イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム |
神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤
|
US6998028B1
(en)
*
|
2004-09-24 |
2006-02-14 |
Superpower, Inc. |
Methods for forming superconducting conductors
|
SI1797127T1
(sl)
*
|
2004-09-24 |
2017-09-29 |
Amgen Inc. |
Modificirane fc-molekule
|
US8435948B2
(en)
|
2004-09-29 |
2013-05-07 |
Mount Sinai School Of Medicine Of New York University |
Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
|
WO2006042112A2
(en)
|
2004-10-05 |
2006-04-20 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
SG165344A1
(en)
|
2004-10-05 |
2010-10-28 |
Genentech Inc |
Method for treating vasculitis
|
MX2007004176A
(es)
*
|
2004-10-06 |
2007-06-15 |
Mayo Foundation |
B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
|
JP2008515929A
(ja)
*
|
2004-10-08 |
2008-05-15 |
アルザ コーポレイション |
脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
PL1827500T3
(pl)
*
|
2004-10-26 |
2009-09-30 |
Pharma Mar Sa |
Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
|
US20060110441A1
(en)
*
|
2004-10-28 |
2006-05-25 |
Harry Wong |
Lyophilized liposome formulations and method
|
NZ554761A
(en)
|
2004-10-29 |
2010-01-29 |
Pharma Mar Sa |
Formulations comprising ecteinascidin and a disaccharide
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
WO2006052767A2
(en)
|
2004-11-05 |
2006-05-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
KR20070089693A
(ko)
*
|
2004-11-08 |
2007-08-31 |
트랜세이브, 인코포레이티드 |
지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
|
EP1814910A4
(de)
*
|
2004-11-11 |
2009-04-29 |
Affymax Inc |
Neue am erythropoietinrezeptor bindende peptide
|
AU2005303389A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
CA2587411A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
EP1813288B1
(de)
*
|
2004-11-18 |
2018-07-18 |
Terumo Kabushiki Kaisha |
Medizinische zusammensetzung, medizinische zubereitung und kombinationspräparat
|
EP1824872B1
(de)
*
|
2004-12-14 |
2012-02-08 |
Alnylam Pharmaceuticals Inc. |
Rnai-modulation von mll-af4 und verwendungen dafür
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
KR20190110637A
(ko)
|
2005-01-21 |
2019-09-30 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
US9937127B2
(en)
*
|
2005-01-28 |
2018-04-10 |
Kyowa Hakko Kirin Co., Ltd. |
Method of producing fine particles surface-modified with water-soluble substance
|
US20090028889A1
(en)
|
2005-01-31 |
2009-01-29 |
Vaxinnate Corporation |
Novel Polypeptide Ligands For Toll-Like Receptor 2 (TLR2)
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
CA2598409A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
CN101238142B
(zh)
*
|
2005-02-18 |
2012-11-14 |
国立大学法人德岛大学 |
含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
|
EP1871807B1
(de)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen cxcr4 und anwendungsverfahren dafür
|
RU2404806C2
(ru)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
US20090110633A1
(en)
*
|
2005-03-14 |
2009-04-30 |
Shiladitya Sengupta |
Nanocells for Diagnosis and Treatment of Diseases and Disorders
|
JP2008538351A
(ja)
|
2005-03-21 |
2008-10-23 |
メタボレックス インコーポレーティッド |
癌を含むPPARγ反応性疾患の処置または予防における浮腫を回避するための方法
|
CN1840193B
(zh)
*
|
2005-03-29 |
2010-05-12 |
中国科学院生物物理研究所 |
聚乙二醇化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂
|
ATE541928T1
(de)
|
2005-03-31 |
2012-02-15 |
Calando Pharmaceuticals Inc |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
EP1891111A1
(de)
|
2005-05-06 |
2008-02-27 |
ZymoGenetics, Inc. |
Monoklonale il-31-antikörper und anwendungsverfahren
|
EP3805245A1
(de)
|
2005-05-17 |
2021-04-14 |
University of Connecticut |
Zusammensetzungen und verfahren zur immunomodulation in einem organismus
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
EP1907425B1
(de)
|
2005-07-22 |
2014-01-08 |
Y's Therapeutics Co., Ltd. |
Anti-cd26-antikörper und verfahren zu ihrer verwendung
|
EP1913027B1
(de)
*
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf-spezifische monoklonale antikörper und anwendungen davon
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
US8998881B2
(en)
|
2005-08-10 |
2015-04-07 |
Alza Corporation |
Method for delivering drugs to tissue under microjet propulsion
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US10004828B2
(en)
*
|
2005-10-11 |
2018-06-26 |
Romat at Tel-Aviv University Ltd. |
Self-assembled Fmoc-ff hydrogels
|
AR056142A1
(es)
*
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
GB0522082D0
(en)
|
2005-10-31 |
2005-12-07 |
Pharma Mar Sa |
Formulations
|
WO2007053577A2
(en)
|
2005-10-31 |
2007-05-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
KR20080086440A
(ko)
|
2005-11-01 |
2008-09-25 |
알닐람 파마슈티칼스 인코포레이티드 |
인플루엔자 바이러스 복제의 RNAi 억제
|
AU2006308765B2
(en)
|
2005-11-02 |
2013-09-05 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
US20070190180A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
|
US20070190182A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
US20070190181A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
|
AU2006315562C1
(en)
|
2005-11-12 |
2013-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for treating depression using NCAM peptide mimetics
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
SI3045182T1
(en)
|
2005-11-14 |
2018-08-31 |
Teva Pharmaceuticals International Gmbh |
An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
RS54111B1
(en)
|
2005-11-18 |
2015-12-31 |
Glenmark Pharmaceuticals S.A. |
ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
US7807652B2
(en)
|
2005-11-21 |
2010-10-05 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20070122350A1
(en)
*
|
2005-11-30 |
2007-05-31 |
Transave, Inc. |
Safe and effective methods of administering therapeutic agents
|
US8466263B2
(en)
*
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
WO2007066335A2
(en)
*
|
2005-12-08 |
2007-06-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods for affecting liposome composition by ultrasound irradiation
|
US20080300320A1
(en)
*
|
2005-12-09 |
2008-12-04 |
Basf Se |
Use of Polyvinyl Lactam-Polyalkylene Block Copolymers as Solubilisers for Poorly Water-Soluble Compounds
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
US20100015642A1
(en)
*
|
2006-01-05 |
2010-01-21 |
Kwon Eugene D |
B7-h1 and survivin in cancer
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
EP1984024A2
(de)
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
JP5425474B2
(ja)
|
2006-01-26 |
2014-02-26 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
ハンチンチン対する、組成物及びその使用
|
EP2781524A1
(de)
|
2006-01-26 |
2014-09-24 |
Recopharma AB |
Zusammensetzung und Verfahren zur Bekämpfung von viralen Infektionen
|
WO2007130725A2
(en)
*
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20070218116A1
(en)
*
|
2006-03-14 |
2007-09-20 |
Schwendener Reto A |
Compositions and methods for the treatment of tumors and tumor metastases
|
US9119782B2
(en)
*
|
2006-03-20 |
2015-09-01 |
Mary P. McCourt |
Drug delivery means
|
TWI397535B
(zh)
|
2006-03-21 |
2013-06-01 |
Genentech Inc |
包含α5β1拮抗劑之組合治療
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
ES2544861T3
(es)
|
2006-03-31 |
2015-09-04 |
Alnylam Pharmaceuticals Inc. |
Composiciones y métodos para inhibir la expresión del gen Eg5
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
WO2007121522A1
(en)
|
2006-04-21 |
2007-11-01 |
Minister for Primary Industries For And On Behalf Of The State Of New South Wales |
Pestivirus species
|
CA2656990A1
(en)
*
|
2006-04-28 |
2007-11-08 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
US8298818B2
(en)
*
|
2006-04-28 |
2012-10-30 |
University Of Florida Research Foundation, Inc. |
Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
|
WO2008018932A2
(en)
*
|
2006-05-01 |
2008-02-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
|
MX2008014005A
(es)
*
|
2006-05-03 |
2009-01-27 |
Baltic Technology Dev Ltd |
Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
|
WO2007133627A2
(en)
*
|
2006-05-10 |
2007-11-22 |
Alza Corporation |
Method for making liposomes conjugated with temperature-sensitive ligands
|
WO2007133801A2
(en)
*
|
2006-05-15 |
2007-11-22 |
Dmitri B Kirpotin |
Magnetic microparticles comprising organic substances
|
EP2522678A1
(de)
|
2006-05-15 |
2012-11-14 |
Sea Lane Biotechnologies, LLC |
Neutralisierung von Antikörpern der Influenza-Viren
|
US8106013B2
(en)
*
|
2006-05-19 |
2012-01-31 |
Georgia Tech Research Corporation |
ABC transporter ligand GATX1
|
WO2007137156A2
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
US7888498B2
(en)
*
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
EP2023938A4
(de)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation von chrebp-expression
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
CN101489593B
(zh)
*
|
2006-06-19 |
2015-11-25 |
约翰·霍普金斯大学 |
通过脂质体酶的治疗剂肿瘤特异性递送
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
CA2787343C
(en)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprising modified lcat and uses thereof
|
JP5072275B2
(ja)
*
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
EP2471815B1
(de)
|
2006-07-11 |
2016-03-30 |
University Of Medicine And Dentistry Of New Jersey |
Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
|
WO2008008873A2
(en)
*
|
2006-07-14 |
2008-01-17 |
Georgia Tech Research Corporation |
Clc channel ligand
|
US8343539B2
(en)
|
2006-07-14 |
2013-01-01 |
Regents Of The University Of Minnesota |
Compounds that bind α5β1 integrin and methods of use
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
MX2009000696A
(es)
|
2006-07-19 |
2009-01-30 |
Univ Pennsylvania |
Wsx-1/p28 como un objetivo para respuestas anti-inflamatorias.
|
JP4936312B2
(ja)
*
|
2006-07-20 |
2012-05-23 |
株式会社島津製作所 |
新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
|
WO2008013918A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
EP2057193B1
(de)
|
2006-08-04 |
2013-12-18 |
Novartis AG |
Ephb3-spezifischer antikörper und verwendungen davon
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
RS53263B
(en)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
CD19 OPTIMIZED ANTIBODY
|
TWI454480B
(zh)
|
2006-08-18 |
2014-10-01 |
Novartis Ag |
催乳激素受體(prlr)之專一性抗體及其用途
|
WO2008023840A2
(en)
|
2006-08-25 |
2008-02-28 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
MY162024A
(en)
|
2006-08-28 |
2017-05-31 |
La Jolla Inst Allergy & Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
EP2056856B1
(de)
|
2006-08-29 |
2015-01-14 |
Genentech, Inc. |
Verwendung von tenecteplase zur behandlung akuter ischämischer anfälle
|
BRPI0715660B8
(pt)
|
2006-09-01 |
2021-05-25 |
Zymogenetics Inc |
anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
|
CA2600220C
(en)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Surface cross-linked lipidic particles, methods of production and uses therefor
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
MX2009004532A
(es)
|
2006-10-27 |
2009-09-04 |
Lpath Inc |
Composiciones y metodos para unir esfingosina-1-fosfato.
|
WO2008055072A2
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
WO2008058291A2
(en)
*
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
JP2010510175A
(ja)
*
|
2006-11-10 |
2010-04-02 |
ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド |
甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー/オリゴマー
|
JP5313909B2
(ja)
|
2006-11-13 |
2013-10-09 |
アイコス コーポレイション |
炎症性疾患および癌の処置のためのチエノピリミジノン
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
EP1932517A3
(de)
*
|
2006-12-11 |
2008-07-16 |
Universiteit Utrecht Holding B.V. |
Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
|
EP2114413B1
(de)
*
|
2006-12-18 |
2014-10-22 |
The Johns Hopkins University |
Therapeutische mittel zur krebsbehandlung mit 3-brompyruvat
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
US8278415B2
(en)
|
2006-12-21 |
2012-10-02 |
Centocor, Inc. |
Dimeric high affinity EGFR constructs and uses thereof
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
WO2008083169A2
(en)
*
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
EP2124998B8
(de)
|
2006-12-27 |
2015-05-06 |
The Johns Hopkins University |
Verfahren zum nachweis von entzündungs- und autoimmunerkrankungen
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
US7638541B2
(en)
*
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
WO2008086807A2
(en)
*
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
US20100329664A1
(en)
*
|
2007-01-23 |
2010-12-30 |
Lim Dae-Soon |
Shutter device for camera
|
WO2008094945A2
(en)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
WO2008094275A1
(en)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides for treatment of conditions associated with nitric oxide
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
EP2146692A1
(de)
*
|
2007-03-19 |
2010-01-27 |
Fresenius Kabi Oncology Limited |
Proliposomale und liposomale zusammensetzungen
|
JP4510842B2
(ja)
*
|
2007-03-26 |
2010-07-28 |
キヤノン株式会社 |
ポリヒドロキシアルカノエート被覆リポソーム
|
EP2905336A1
(de)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression eines Gens von Ebola
|
EP2164868B1
(de)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
|
EP2068925A4
(de)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
Anti-icos-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
WO2008141274A1
(en)
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Anti-alpha v immunoliposome composition, methods and uses
|
WO2008141276A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Anti-alpha-v immunoliposome composition, methods and uses
|
US20090163698A1
(en)
*
|
2007-05-11 |
2009-06-25 |
John Joseph Grigsby |
Method for Preparing Antibody Conjugates
|
ES2433967T3
(es)
|
2007-05-14 |
2013-12-13 |
The University Of Chicago |
Productos de fusión anticuerpo-LIGHT como productos terapéuticos de cáncer
|
SI2173381T1
(sl)
|
2007-05-14 |
2014-01-31 |
Novimmune Sa |
Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
|
US8420779B2
(en)
*
|
2007-05-22 |
2013-04-16 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008148023A2
(en)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
CA2688240A1
(en)
|
2007-05-24 |
2008-12-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Intranuclear protein transduction through a nucleoside salvage pathway
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
DK2164992T3
(en)
*
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
EP2514762B1
(de)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC-Varianten
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
US20090082217A1
(en)
*
|
2007-07-16 |
2009-03-26 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
EP2185544B1
(de)
*
|
2007-07-19 |
2014-11-26 |
Cymabay Therapeutics, Inc. |
N-azazyklische substituierte pyrrol-, pyrazol-, imidazol-, triazol- und tetrazolderivate als rup3- oder gpr119-agonisten zur behandlung von diabetes und stoffwechselerkrankungen
|
PT2181190E
(pt)
|
2007-07-26 |
2014-02-24 |
Amgen Inc |
Enzimas aciltransferase de lecitina-colesterol modificadas
|
WO2009013202A1
(de)
*
|
2007-07-26 |
2009-01-29 |
Basf Se |
Verfahren zur herstellung von durch pfropfpolymerisation in lösung erhaltenen copolymeren auf basis von polyethern in fester form
|
US7666973B2
(en)
|
2007-07-30 |
2010-02-23 |
Tyco Healthcare Group Lp |
Carbonate copolymers
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
EP2177230A4
(de)
*
|
2007-08-09 |
2011-04-27 |
Daiichi Sankyo Co Ltd |
Immunoliposom als induktor von apoptose in todesdomäne-enthaltenden rezeptor exprimierende zelle
|
US8268958B2
(en)
|
2007-08-15 |
2012-09-18 |
Tyco Healthcare Group Ip |
Phospholipid copolymers
|
US20090048423A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Tyco Healthcare Group Lp |
Phospholipid Copolymers
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
JP2010539089A
(ja)
*
|
2007-09-07 |
2010-12-16 |
ゲンシア コーポレーション |
ミトコンドリア組成物及びその使用
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
US20090104114A1
(en)
*
|
2007-09-21 |
2009-04-23 |
Cytimmune Sciences, Inc. |
Nanotherapeutic Colloidal Metal Compositions and Methods
|
CN106310293A
(zh)
*
|
2007-09-27 |
2017-01-11 |
免疫疫苗技术有限公司 |
在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
|
US20100239652A1
(en)
*
|
2007-09-28 |
2010-09-23 |
Universitatsspital Basel |
Immunoliposomes for treatment of cancer
|
CA2700953A1
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
MX2010003979A
(es)
*
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
Composicion farmaceutica oralmente administrable y proceso para su preparacion.
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
AU2008324068A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
WO2009061818A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
LT2514436T
(lt)
|
2007-11-07 |
2018-04-10 |
Genentech, Inc. |
Il-22 panaudojimas mikrobinių sutrikimų gydymui
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
KR20100097691A
(ko)
|
2007-11-12 |
2010-09-03 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
NZ586611A
(en)
|
2007-12-06 |
2012-09-28 |
Dana Farber Cancer Inst Inc |
Antibodies against influenza virus and methods of use thereof
|
LT2796466T
(lt)
|
2007-12-07 |
2018-02-26 |
Zymogenetics, Inc. |
Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
|
EP2617828B1
(de)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
RU2570559C2
(ru)
|
2007-12-17 |
2015-12-10 |
Пфайзер Лимитед |
Лечение интерстициального цистита
|
WO2009086514A1
(en)
|
2007-12-28 |
2009-07-09 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
US20090181094A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Eric Yueh-Lang Sheu |
Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MX2010008437A
(es)
|
2008-01-31 |
2010-11-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
AU2009221775B2
(en)
*
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
MX2010009885A
(es)
*
|
2008-03-10 |
2010-11-30 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
|
EP2105145A1
(de)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
US20100040635A1
(en)
|
2008-03-28 |
2010-02-18 |
Sea Lane Biotechnologies |
Neutralizing antibodies to influenza viruses
|
KR20100134659A
(ko)
*
|
2008-03-31 |
2010-12-23 |
메타볼렉스, 인코포레이티드 |
옥시메틸렌 아릴 화합물 및 그것의 사용
|
WO2009123764A2
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
EP2279412B1
(de)
|
2008-04-09 |
2017-07-26 |
Genentech, Inc. |
Neue zusammensetzungen und verfahren zur behandlung von immunkrankheiten
|
JP2011516078A
(ja)
|
2008-04-10 |
2011-05-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
癌におけるegfr突然変異を検出する組成物および方法
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
CA2722668A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Wyeth Llc |
Methods for treating inflammation
|
AU2009245358A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
WO2009136297A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
CA2723614C
(en)
|
2008-05-16 |
2015-07-14 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
CN105363034A
(zh)
*
|
2008-05-23 |
2016-03-02 |
香港大学 |
治疗流感的联合疗法
|
EP2305214B1
(de)
|
2008-06-05 |
2018-01-03 |
Shimadzu Corporation |
Neue molekulare anordnung, molekulare sonde zur molekularen bildgebung und molekulare sonde für ein arzneiabgabesystem damit sowie molekulares bildgebungssystem und arzneiabgabesystem
|
ES2524699T3
(es)
*
|
2008-06-05 |
2014-12-11 |
Immunovaccine Technologies Inc. |
Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2009155431A1
(en)
*
|
2008-06-18 |
2009-12-23 |
University Of Louisville Research Foundation, Inc. |
Methods for targeted cancer treatment and detection
|
US20100003315A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
CN102112490B
(zh)
|
2008-07-08 |
2014-10-22 |
昂考梅德药品有限公司 |
Notch1受体结合剂和其使用方法
|
EP2310440A4
(de)
*
|
2008-07-10 |
2013-06-05 |
Serina Therapeutics Inc |
Polyoxazoline mit inerten endgruppen, aus geschützten anfangsgruppen hergestellte polyoxazoline und entsprechende verbindungen
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
JP2012500197A
(ja)
|
2008-08-15 |
2012-01-05 |
ジョージタウン ユニバーシティー |
Rassf1a発現およびヒト癌細胞増殖の蛍光調節剤
|
DK2331092T3
(da)
|
2008-08-21 |
2014-05-19 |
Univ Johns Hopkins |
Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
|
JP5656834B2
(ja)
|
2008-08-22 |
2015-01-21 |
サノフイ |
肥満細胞トリプターゼインヒビターとしての[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−[7−フルオロ−1−(2−メトキシ−エチル)−4−トリフルオロメトキシ−1h−インドール−3−イル]−メタノン
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
AU2009275387B2
(en)
|
2008-08-25 |
2010-07-08 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
US20110223188A1
(en)
*
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
AU2009291747B2
(en)
|
2008-09-10 |
2016-05-26 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
WO2010033248A2
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
EP3584320A1
(de)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
WO2010042823A1
(en)
|
2008-10-09 |
2010-04-15 |
Northeastern Universtiy |
Multifunctional self-assembling polymeric nanosystems
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
CN106834291B
(zh)
|
2008-10-20 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
抑制运甲状腺素蛋白表达的组合物和方法
|
EP2342217B1
(de)
*
|
2008-10-21 |
2015-12-23 |
International Vaccine Institute |
Neue chigellaproteinantigene und verfahren
|
BRPI0920237A2
(pt)
|
2008-10-21 |
2015-12-29 |
Metabolex Inc |
agonistas do receptor aril gpr120 e suas respectivas utilizações
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
JP5775458B2
(ja)
*
|
2008-11-06 |
2015-09-09 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
抗α2インテグリン抗体を使用する処置
|
EP3699172A3
(de)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US20100202963A1
(en)
|
2008-11-13 |
2010-08-12 |
Gallatin W Michael |
Therapies for hematologic malignancies
|
JP6041489B2
(ja)
|
2008-11-22 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
乳癌の治療のための化学療法と併用した抗vegf抗体の使用
|
US20110230399A1
(en)
*
|
2008-11-25 |
2011-09-22 |
Bowen Richard L |
Methods for Treating Obesity Related Disease
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
US8628762B2
(en)
|
2008-12-10 |
2014-01-14 |
Icahn School Of Medicine At Mount Sinai |
T-helper cell type 17 lineage-specific adjuvants, compositions and methods
|
AR074776A1
(es)
|
2008-12-18 |
2011-02-09 |
Sanofi Aventis |
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
MX2011006456A
(es)
|
2008-12-22 |
2011-10-11 |
Creabilis S A |
Sintesis de conjugados de polimero de compuestos de indolocarbazola.
|
EA019295B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Соединения пуриновых нуклеозидов и способ их получения
|
NZ617066A
(en)
|
2008-12-23 |
2015-02-27 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2560107T3
(es)
|
2009-02-12 |
2016-02-17 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
WO2010093906A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
WO2010102058A2
(en)
|
2009-03-04 |
2010-09-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
EP2228059A1
(de)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Chemotherapeutische Zusammensetzung für die Krebsbehandlung
|
CA2755409C
(en)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
KR20120002995A
(ko)
|
2009-03-24 |
2012-01-09 |
길리아드 칼리스토가 엘엘씨 |
2―퓨리닐―3―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
|
UA108199C2
(uk)
|
2009-03-25 |
2015-04-10 |
|
АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
JP5795306B2
(ja)
|
2009-04-01 |
2015-10-14 |
ジェネンテック, インコーポレイテッド |
インスリン抵抗性疾患の治療
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
CN102458410A
(zh)
*
|
2009-04-20 |
2012-05-16 |
吉联亚·卡利斯托加有限责任公司 |
治疗实体瘤的方法
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
CA2759506A1
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
JP2012525149A
(ja)
*
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
EP2248903A1
(de)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
|
WO2010127271A1
(en)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
US8524784B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
EP2427203B1
(de)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f-antikörper und deren verwendung
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
ES2664590T3
(es)
|
2009-05-18 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
US8158601B2
(en)
|
2009-06-10 |
2012-04-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulation
|
EP2440250A1
(de)
|
2009-06-11 |
2012-04-18 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Gezielt ausgerichtete liposome mit n-haltigen bisphosphonaten und ihre verwendung
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療
|
KR101829073B1
(ko)
|
2009-06-26 |
2018-02-13 |
아이2 파마슈티컬스, 인크. |
대리 경쇄의 발현
|
EP2446037B1
(de)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
|
EP2450055B1
(de)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Verfahren zur unterdrückung des nierentumorwachstums mittels blockierung des fibroblastenwachstumsfaktor-rezektors
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011005715A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
WO2011006510A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Technical University Of Denmark |
Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
|
CA2768843A1
(en)
|
2009-07-21 |
2011-01-27 |
Gilead Calistoga Llc |
Treatment of liver disorders with pi3k inhibitors
|
WO2011017297A2
(en)
*
|
2009-08-03 |
2011-02-10 |
The University Of North Carolina At Chapel Hill |
Biodegradable delivery system complexes for the delivery of bioactive compounds
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
WO2011020023A2
(en)
|
2009-08-14 |
2011-02-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
WO2011022264A1
(en)
|
2009-08-15 |
2011-02-24 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
CA2772199A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
JP5909185B2
(ja)
|
2009-10-01 |
2016-04-26 |
シマベイ セラピューティクス, インコーポレーテッド |
置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩
|
EP4089169A1
(de)
|
2009-10-12 |
2022-11-16 |
Larry J. Smith |
Verfahren und zusammensetzungen zum modulieren der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
|
EP2488643A4
(de)
*
|
2009-10-15 |
2013-07-03 |
Hoffmann La Roche |
Chimäre fibroblastwachstumsfaktoren mit veränderter rezeptorspezifizität
|
JP5965318B2
(ja)
|
2009-10-16 |
2016-08-03 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
EP2493468A1
(de)
|
2009-10-30 |
2012-09-05 |
Sanofi |
Aminobenzoesäurederivate zur verwendung bei der behandlung von krankheiten im zusammenhang mit dihydrogenase
|
CA2779574C
(en)
|
2009-11-05 |
2018-12-18 |
Rhizen Pharmaceuticals S.A. |
Novel kinase modulators
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
CA2783934A1
(en)
|
2009-12-11 |
2011-06-16 |
Genecode As |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
|
US20130004490A1
(en)
|
2009-12-14 |
2013-01-03 |
The United States of America, as represented by the Secretary, Department |
Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
|
ES2661813T3
(es)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
|
EP2513308B1
(de)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation von pilr zur behandlung immunerkrankungen
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
JP5934106B2
(ja)
|
2009-12-23 |
2016-06-15 |
カッパーアールエヌエー,インコーポレイテッド |
肝細胞増殖因子(hgf)に対する天然アンチセンス転写物の阻害によるhgf関連性疾患の治療
|
CA2785439A1
(en)
|
2009-12-23 |
2011-06-30 |
Sanofi |
[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
MX2012006739A
(es)
|
2009-12-23 |
2012-06-28 |
Sanofi Sa |
Profarmacos de [4 [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il] -(1h-pirrolo-piridin-il)-metanonas y sintesis de estos.
|
SI2516468T1
(sl)
|
2009-12-23 |
2016-06-30 |
Synimmune Gmbh |
Protitelesa proti flt3 in postopki uporabe istih
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011080796A1
(en)
|
2009-12-28 |
2011-07-07 |
Oncotherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
US8921334B2
(en)
|
2009-12-29 |
2014-12-30 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
|
EP2519634B1
(de)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
US8961929B2
(en)
|
2010-01-08 |
2015-02-24 |
Fujifilm Corporation |
Targeting agent for tumor site
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
EP2525808A2
(de)
|
2010-01-19 |
2012-11-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin als behandlungsmittel für männliche fortpflanzungsstörungen
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
US8198337B2
(en)
*
|
2010-01-27 |
2012-06-12 |
Momentive Performance Materials Inc. |
Demulsifier compositions and methods for separating emulsions using the same
|
EP2531175A2
(de)
|
2010-02-01 |
2012-12-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomen mit amphipathischen wirkstoffen und herstellungsverfahren dafür
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
EP3696194A1
(de)
|
2010-02-23 |
2020-08-19 |
F. Hoffmann-La Roche AG |
Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
|
US8975376B2
(en)
|
2010-02-23 |
2015-03-10 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
US8877897B2
(en)
|
2010-02-23 |
2014-11-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
CA2791278C
(en)
|
2010-02-25 |
2015-11-24 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
KR20120138241A
(ko)
|
2010-03-11 |
2012-12-24 |
화이자 인코포레이티드 |
pH 의존성 항원 결합을 갖는 항체
|
KR20180000342A
(ko)
|
2010-03-22 |
2018-01-02 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
AU2011235044A1
(en)
|
2010-03-31 |
2012-11-22 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
EP2552933A1
(de)
|
2010-03-31 |
2013-02-06 |
Gilead Pharmasset LLC |
Purin-nukleosid-phosphoramidat
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
MY187990A
(en)
|
2010-03-31 |
2021-11-07 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
US9073990B2
(en)
|
2010-04-05 |
2015-07-07 |
Bar-Llan University |
Protease-activatable pore-forming polypeptides
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9096660B2
(en)
|
2010-04-26 |
2015-08-04 |
Abraxis Bioscience, Llc |
SPARC binding antibodies and uses thereof
|
WO2011135905A1
(ja)
*
|
2010-04-28 |
2011-11-03 |
国立大学法人北海道大学 |
脂質膜構造体
|
SI2563920T1
(sl)
|
2010-04-29 |
2017-05-31 |
Ionis Pharmaceuticals, Inc. |
Modulacija izražanja transtiretina
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
ES2623799T3
(es)
|
2010-04-30 |
2017-07-12 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
WO2011139387A1
(en)
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
ES2705236T3
(es)
|
2010-05-12 |
2019-03-22 |
Univ Columbia |
Procedimientos para producir células enteroendocrinas que producen y secretan insulina
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
EP2571878B1
(de)
|
2010-05-17 |
2018-10-17 |
Incozen Therapeutics Pvt. Ltd. |
Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte -3h-[1,2,3]triazol[4,5-b]pyridin- verbindungen als proteinkinasemodulatoren
|
DK2571516T3
(en)
|
2010-05-18 |
2018-02-05 |
Neumedicines Inc |
IL-12 FORMULATIONS FOR STIMULATING HEMOPOIES
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
NO2576783T3
(de)
|
2010-05-26 |
2018-04-28 |
|
|
AU2011261396B2
(en)
|
2010-06-02 |
2015-11-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CN103096875B
(zh)
|
2010-06-03 |
2016-08-17 |
阿尔尼拉姆医药品有限公司 |
用于递送活性剂的生物可降解脂质
|
DK2582674T3
(en)
|
2010-06-16 |
2014-12-15 |
Cymabay Therapeutics Inc |
GPR120 receptor agonists and uses thereof.
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
JP2013529638A
(ja)
*
|
2010-06-19 |
2013-07-22 |
ウェスタン ユニバーシティ オブ ヘルス サイエンス |
Peg化リポソーム封入糖ペプチド抗生物質の新規製剤
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
SI3586826T1
(sl)
|
2010-06-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
|
CN102309448B
(zh)
*
|
2010-06-29 |
2014-07-09 |
中国人民解放军军事医学科学院毒物药物研究所 |
一种肺部给药的环丙沙星药用组合物及其制备方法
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
BR112013000392B8
(pt)
|
2010-07-06 |
2022-10-04 |
Novartis Ag |
Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
|
SI2590626T1
(sl)
|
2010-07-06 |
2016-01-29 |
Glaxosmithkline Biologicals S.A. |
Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
|
LT3243526T
(lt)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
EP2593142B8
(de)
|
2010-07-12 |
2018-12-26 |
Pfizer Healthcare Ireland |
Multifunktionelle antikörperkonjugate
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012019093A1
(en)
|
2010-08-05 |
2012-02-09 |
Human Biomolecular Research Institute |
Synthetic compounds and methods to decrease nicotine self-administration
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
EP2603237A4
(de)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
Anti-hämagglutinin-antikörperzusammensetzungen und verfahren zu ihrer anwendung
|
CA3201524A1
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
SI4008357T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするrnaの送達のためのpeg化リポソーム
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
US20140030292A1
(en)
|
2010-10-11 |
2014-01-30 |
Novartis Ag |
Antigen delivery platforms
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
WO2012061129A1
(en)
|
2010-10-25 |
2012-05-10 |
Genentech, Inc |
Treatment of gastrointestinal inflammation and psoriasis a
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
EA201890548A1
(ru)
|
2010-11-04 |
2018-07-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела к il-23
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2012065044A2
(en)
|
2010-11-12 |
2012-05-18 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
WO2012099566A1
(en)
|
2010-11-17 |
2012-07-26 |
Sea Lane Biotechnologies, Llc |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
AU2011329638C1
(en)
|
2010-11-18 |
2017-04-27 |
The General Hospital Corporation |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
DK2651447T3
(en)
|
2010-12-14 |
2018-12-17 |
Univ Denmark Tech Dtu |
Capture of radionuclides in nanoparticle compositions
|
EP2468259A1
(de)
*
|
2010-12-23 |
2012-06-27 |
Traslational Cancer Drugs Pharma, S.L. |
Pharmazeutische Zusammensetzungen aus Pyridinium- und Chinoliniumderivaten
|
AU2011353698B2
(en)
|
2011-01-05 |
2017-05-11 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
CA2821985C
(en)
|
2011-01-11 |
2019-07-09 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
WO2012106508A1
(en)
|
2011-02-02 |
2012-08-09 |
Pfizer Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
WO2012112489A2
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PL226015B1
(pl)
*
|
2011-03-03 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
|
KR20190107761A
(ko)
|
2011-03-09 |
2019-09-20 |
셀 시그널링 테크놀러지, 인크. |
모노클로날 항체를 생성하는 방법 및 시약
|
WO2012125614A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PE20140593A1
(es)
|
2011-03-16 |
2014-05-10 |
Amgen Inc |
Inhibidores potentes y selectivos de nav1.3 y nav1.7
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
WO2012134975A1
(en)
|
2011-03-28 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
EP3412309A1
(de)
|
2011-03-31 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Verfahren zur verabreichung von beta7-integrin-antagonisten
|
EP2508176A1
(de)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Neues Kombinatonsbehandlung für Krebs
|
WO2012142458A1
(en)
|
2011-04-13 |
2012-10-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-emapii 항체 및 이의 용도
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
|
MX365160B
(es)
|
2011-05-04 |
2019-05-24 |
Rhizen Pharmaceuticals Sa |
Compuestos novedosos como moduladores de proteína cinasas.
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
KR101970634B1
(ko)
|
2011-06-02 |
2019-04-19 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
생체외 조직 배양 시스템을 위한 방법 및 용도
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
EP2721156B1
(de)
|
2011-06-16 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4
|
EP2723865B1
(de)
|
2011-06-21 |
2019-03-27 |
Alnylam Pharmaceuticals, Inc. |
VERFAHREN ZUR BESTIMMUNG DER AKTIVITÄT VON RNAi IN EINEM PATIENTEN
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
EP2537532A1
(de)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
CA2839451A1
(en)
|
2011-06-27 |
2013-01-03 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
US20150045540A1
(en)
|
2011-06-28 |
2015-02-12 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
WO2013008240A2
(en)
|
2011-07-13 |
2013-01-17 |
Yissum Research Development Company Of The Hebrew University Ofjerusalem Ltd. |
Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
|
RU2576034C2
(ru)
|
2011-07-14 |
2016-02-27 |
Пфайзер Инк. |
Лечение антителами против pcsk9
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
EP2739735A2
(de)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
FR2979239A1
(fr)
*
|
2011-08-25 |
2013-03-01 |
Trophos |
Liposome comprenant au moins un derive de cholesterol
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
JP6228121B2
(ja)
|
2011-08-31 |
2017-11-08 |
セント ジュード チルドレンズ リサーチ ホスピタル |
リソソームエキソサイトーシス活性のレベルを検出する方法及び組成物並びに使用方法
|
SG11201400100SA
(en)
|
2011-09-09 |
2014-06-27 |
Univ Osaka |
Dengue-virus serotype neutralizing antibodies
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
WO2013043580A2
(en)
|
2011-09-19 |
2013-03-28 |
Gencia Corporation |
Modified creatine compounds
|
EP2758533B1
(de)
|
2011-09-20 |
2018-04-11 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulation der gcgr-expression
|
JP2014530001A
(ja)
|
2011-09-23 |
2014-11-17 |
テクノファージ, インベスティガサン エデセンボルビメント エム ビオテクノロジア,エスエー |
抗腫瘍壊死因子−α剤及びその使用
|
EP3485903B1
(de)
|
2011-09-23 |
2022-11-16 |
Mereo BioPharma 5, Inc. |
Vegf/dll4-bindende stoffe und ihre verwendung
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2013049749A2
(en)
|
2011-09-29 |
2013-04-04 |
Plx Pharma Inc. |
pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
AU2012321022B2
(en)
|
2011-10-06 |
2017-03-23 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
|
PT2766393T
(pt)
|
2011-10-14 |
2018-10-15 |
Hoffmann La Roche |
Anticorpos anti-htra1 e métodos de utilização
|
US8883989B2
(en)
|
2011-10-18 |
2014-11-11 |
Regents Of The University Of Minnesota |
Fractalkine binding polynucleotides and methods of use
|
IN2014CN03749A
(de)
|
2011-10-25 |
2015-09-25 |
Isis Pharmaceuticals Inc |
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
AR088509A1
(es)
|
2011-10-28 |
2014-06-11 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
KR20140084078A
(ko)
|
2011-10-31 |
2014-07-04 |
제넨테크, 인크. |
항체 제제
|
WO2013067449A1
(en)
*
|
2011-11-03 |
2013-05-10 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
EP2776470A2
(de)
|
2011-11-11 |
2014-09-17 |
Rinat Neuroscience Corporation |
Für trop-2 spezifische antikörper und ihre verwendungen
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
SG11201402283PA
(en)
|
2011-11-16 |
2014-06-27 |
Boehringer Ingelheim Int |
Anti il-36r antibodies
|
CN104284680A
(zh)
|
2011-12-15 |
2015-01-14 |
芝加哥大学 |
使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013093707A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US20130323234A1
(en)
|
2012-01-09 |
2013-12-05 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
US9636381B2
(en)
|
2012-01-18 |
2017-05-02 |
Neumedicines, Inc. |
Methods for radiation protection by administering IL-12
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
US20150004219A1
(en)
|
2012-02-02 |
2015-01-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Stable liposomes for drug delivery
|
CA2863834A1
(en)
|
2012-02-06 |
2013-08-15 |
Inhibrx Llc |
Cd47 antibodies and methods of use thereof
|
AU2013221292A1
(en)
*
|
2012-02-17 |
2014-09-11 |
Celsion Corporation |
Thermosensitive nanoparticle formulations and method of making the same
|
US9138492B2
(en)
*
|
2012-02-23 |
2015-09-22 |
Canon Kabushiki Kaisha |
Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
|
JP6407726B2
(ja)
|
2012-03-01 |
2018-10-24 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
長寿命ポリペプチド結合分子
|
SI2834241T1
(sl)
|
2012-03-05 |
2021-06-30 |
Gilead Calistoga Llc |
Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
|
CN110438125A
(zh)
|
2012-03-15 |
2019-11-12 |
科纳公司 |
通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
KR20140144726A
(ko)
|
2012-03-30 |
2014-12-19 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
CN104520315A
(zh)
|
2012-04-24 |
2015-04-15 |
迈阿密大学 |
Perforin 2 对侵袭性且多药耐受的病原体的防御
|
CN109206516A
(zh)
|
2012-05-03 |
2019-01-15 |
勃林格殷格翰国际有限公司 |
抗IL-23p19抗体
|
EP2849728A1
(de)
|
2012-05-04 |
2015-03-25 |
The Johns Hopkins University |
Arzneimittelträger auf lipidbasis zur schnellen penetration durch schleimauskleidungen
|
CA2871751C
(en)
|
2012-05-04 |
2021-08-24 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
WO2013188763A1
(en)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
MX363455B
(es)
|
2012-07-18 |
2019-03-25 |
Onyx Therapeutics Inc |
Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
CN103565745A
(zh)
|
2012-08-10 |
2014-02-12 |
德克萨斯州大学系统董事会 |
用于治疗中风的神经保护性脂质体组合物和方法
|
SG11201408340SA
(en)
|
2012-08-14 |
2015-01-29 |
Univ Nanyang Tech |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
CN105025904A
(zh)
|
2012-09-04 |
2015-11-04 |
埃莱森制药有限责任公司 |
用顺铂脂质复合物预防癌症的肺部复发
|
US20160136159A1
(en)
|
2012-09-17 |
2016-05-19 |
Chemedest Ltd. |
Method for Treating Peripheral Neuropathy
|
AU2013326901B2
(en)
|
2012-10-04 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-PD-L1 antibodies and methods of use
|
CA2884368C
(en)
|
2012-10-05 |
2022-01-18 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
CN104768579A
(zh)
|
2012-10-23 |
2015-07-08 |
昂科梅德制药有限公司 |
使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストによる処置の方法およびモニタリング
|
EP3725807A1
(de)
|
2012-12-03 |
2020-10-21 |
NovImmune SA |
Anti-cd47-antikörper und verfahren zur verwendung davon
|
AU2013360302C1
(en)
|
2012-12-12 |
2019-01-24 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
EP2934303B1
(de)
|
2012-12-19 |
2019-09-04 |
The Research Foundation for the State University of New York |
Zusammensetzungen und verfahren für eine durch licht ausgelöste freisetzung von materialien aus nanovesikeln
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
EP2935311B1
(de)
|
2012-12-20 |
2021-03-31 |
Amgen Inc. |
Apj-rezeptoragonisten und verwendungen davon
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
KR20150100715A
(ko)
|
2012-12-21 |
2015-09-02 |
앰플리뮨, 인크. |
항-h7cr 항체
|
WO2014107731A1
(en)
|
2013-01-07 |
2014-07-10 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type 2 infections
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
WO2014124006A1
(en)
|
2013-02-05 |
2014-08-14 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
CA2900468A1
(en)
|
2013-02-06 |
2014-08-14 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
WO2014126921A1
(en)
|
2013-02-12 |
2014-08-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize norovirus
|
UY35397A
(es)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
EP2970369B1
(de)
|
2013-03-14 |
2023-11-22 |
TheraSyn Sensors, Inc. |
Cholestosomvesikel zur inkorporation von molekülen in chylomikronen
|
CA2907175C
(en)
*
|
2013-03-15 |
2022-11-08 |
M. Alphabet 3, L.L.C. |
Methods and compositions for enhancing oxygen levels in tissues
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
AU2014227952A1
(en)
|
2013-03-15 |
2015-10-22 |
Gencia Corporation |
Compositions and methods for treating conditions that affect epidermis
|
SI2970449T1
(sl)
|
2013-03-15 |
2019-11-29 |
Amgen Res Munich Gmbh |
Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
|
CA2901358C
(en)
|
2013-03-15 |
2022-07-26 |
Dana-Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
EP2970446A1
(de)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antikörperkonstrukte für influenza m2 und cd3
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
WO2014152232A2
(en)
|
2013-03-15 |
2014-09-25 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
EP3495814A3
(de)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
|
WO2014169272A1
(en)
|
2013-04-12 |
2014-10-16 |
Icahn School Of Medicine At Mount Sinai |
Method for treating post-traumatic stress disorder
|
ES2822584T3
(es)
|
2013-05-03 |
2021-05-04 |
Univ California |
Inducción de dinucleótidos cíclicos del interferón tipo I
|
SG10201800800YA
(en)
|
2013-05-06 |
2018-03-28 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
CN105189560A
(zh)
|
2013-05-07 |
2015-12-23 |
瑞纳神经科学公司 |
抗胰高血糖素受体抗体和其使用方法
|
US10000556B2
(en)
|
2013-05-09 |
2018-06-19 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
|
CA2913312A1
(en)
|
2013-05-24 |
2014-11-27 |
Medimmune, Llc |
Anti-b7-h5 antibodies and their uses
|
MX369758B
(es)
|
2013-05-31 |
2019-11-20 |
Genentech Inc |
Anticuerpos anti-acido teicoico de pared y conjugados.
|
JP6469094B2
(ja)
|
2013-05-31 |
2019-02-13 |
ジェネンテック, インコーポレイテッド |
抗細胞壁タイコ酸抗体及びコンジュゲート
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
JP6869720B2
(ja)
|
2013-06-13 |
2021-05-12 |
アンチセンス セラピューティクス リミテッド |
併用療法
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR102216088B1
(ko)
|
2013-07-25 |
2021-02-15 |
싸이톰스 테라퓨틱스, 인크. |
다중특이성 항체, 다중특이성 활성화 가능한 항체 및 그의 사용 방법
|
WO2015017807A1
(en)
*
|
2013-08-01 |
2015-02-05 |
University Of Georgia Research Foundation, Inc. |
Liposomal formulations for the treatment of bacterial infections
|
TWI623551B
(zh)
|
2013-08-02 |
2018-05-11 |
輝瑞大藥廠 |
抗cxcr4抗體及抗體-藥物結合物
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
EP3038600B1
(de)
*
|
2013-08-27 |
2020-06-03 |
Northeastern University |
System zur freisetzung von wirkstoffen in nanopartikelform und verfahren zur behandlung von krebs und neurotraumata
|
EP3690048A1
(de)
|
2013-09-04 |
2020-08-05 |
Cold Spring Harbor Laboratory |
Reduzierung von fehlvermitteltem mrna-abbau
|
EP3041935A1
(de)
|
2013-09-05 |
2016-07-13 |
Sage Therapeutics, Inc. |
Antisense-induzierter exon2-einschluss in saurer alpha-glucosidase
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
EP3046537B1
(de)
*
|
2013-09-16 |
2021-07-14 |
Glycomine, Inc. |
Pharmazeutische zubereitung von kohlenhydraten zur therapeutischen verwendung
|
DE102013015334A1
(de)
*
|
2013-09-17 |
2015-03-19 |
Fresenius Medical Care Deutschland Gmbh |
Magnesium-Liposomen-Komplexe
|
EP3047023B1
(de)
|
2013-09-19 |
2019-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
|
MX2016003957A
(es)
|
2013-09-25 |
2017-02-02 |
Cytomx Therapeutics Inc |
Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos.
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
MX2016004230A
(es)
|
2013-10-02 |
2016-10-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
SG11201602631XA
(en)
|
2013-10-04 |
2016-05-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
JPWO2015068781A1
(ja)
|
2013-11-06 |
2017-03-09 |
国立大学法人大阪大学 |
インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015089375A1
(en)
|
2013-12-13 |
2015-06-18 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
NZ720867A
(en)
|
2013-12-20 |
2018-01-26 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
EP3083623A1
(de)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
|
AU2015206629B2
(en)
|
2014-01-14 |
2020-03-05 |
The Johns Hopkins University |
Cyclodextrin compositions encapsulating a selective ATP inhibitor and uses thereof
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
CN105873949A
(zh)
|
2014-01-31 |
2016-08-17 |
勃林格殷格翰国际有限公司 |
新的抗baff抗体
|
RU2016135239A
(ru)
|
2014-01-31 |
2018-03-12 |
Сайтомкс Терапьютикс, Инк. |
Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
JP6870988B2
(ja)
|
2014-02-24 |
2021-05-19 |
セルジーン コーポレイション |
神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
AU2015231164B2
(en)
|
2014-03-19 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
AU2015230933B2
(en)
|
2014-03-21 |
2020-08-13 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
AR099856A1
(es)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
KR102275513B1
(ko)
|
2014-04-30 |
2021-07-08 |
화이자 인코포레이티드 |
항-ptk7 항체-약물 접합체
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
EP3143043B1
(de)
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispezifische antikörper mit modifizierten ch1-cl interaktionen
|
EA028614B1
(ru)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
CN106714830B
(zh)
|
2014-05-30 |
2020-08-25 |
上海复宏汉霖生物技术股份有限公司 |
抗表皮生长因子受体(egfr)抗体
|
CA2951391C
(en)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Apelin polypeptides
|
MX2016016295A
(es)
|
2014-06-11 |
2017-03-31 |
Gilead Sciences Inc |
Metodos para tratar enfermedades cardiovasculares.
|
US11021467B2
(en)
|
2014-06-13 |
2021-06-01 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
JP6655074B2
(ja)
|
2014-06-20 |
2020-02-26 |
ジェネンテック, インコーポレイテッド |
シャガシンに基づく足場組成物、方法及び使用
|
EP3160503B1
(de)
|
2014-06-26 |
2021-02-17 |
The Trustees of Columbia University in the City of New York |
Hemmung der serotoninexpression in enteroendokrinen darmzellenergebnissen bei der umwandlung in insulinpositive zellen
|
WO2016014148A1
(en)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
MX2017001401A
(es)
|
2014-07-31 |
2017-08-07 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016020798A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016034968A1
(en)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Therapeutic antibody
|
WO2016046684A1
(en)
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
US10463732B2
(en)
|
2014-10-03 |
2019-11-05 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
US10675349B2
(en)
|
2014-10-06 |
2020-06-09 |
Dana-Farber Cancer Institute, Inc. |
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
|
GB201417589D0
(en)
|
2014-10-06 |
2014-11-19 |
Cantab Biopharmaceuticals Patents Ltd |
Pharmaceutical Formulations
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016077566A1
(en)
|
2014-11-12 |
2016-05-19 |
Research Institute At Nationwide Children's Hospital |
Modulation of alternative mdm2 splicing
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
EP3226911A1
(de)
|
2014-12-03 |
2017-10-11 |
F.Hoffmann-La Roche Ag |
Antikörper gegen staphylococcus aureus mit rifamycinkonjugaten und verwendungen davon
|
BR112017011478A2
(pt)
|
2014-12-03 |
2018-02-27 |
Genentech, Inc. |
composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
ES2934940T3
(es)
|
2014-12-11 |
2023-02-28 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
AU2015362621B2
(en)
|
2014-12-15 |
2019-01-17 |
The Johns Hopkins University |
Sunitinib formulations and methods for use thereof in treatment of ocular disorders
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
CA2974369A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
AU2016211696B2
(en)
|
2015-01-27 |
2018-05-10 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
US20180215801A1
(en)
|
2015-01-29 |
2018-08-02 |
Board Of Trustees Of Michigan State University |
Cryptic polypeptides and uses thereof
|
US20160250177A1
(en)
*
|
2015-02-17 |
2016-09-01 |
Mallinckrodt Llc |
Modified docetaxel liposome formulations and uses thereof
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
CN107580500B
(zh)
|
2015-02-19 |
2023-05-30 |
康姆普根有限公司 |
抗pvrig抗体和使用方法
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
US10736845B2
(en)
*
|
2015-03-03 |
2020-08-11 |
Cureport Inc. |
Dual loaded liposomal pharmaceutical formulations
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
EP3265059A4
(de)
|
2015-03-03 |
2018-08-29 |
Cureport Inc. |
Liposomale pharmazeutische kombinationsformulierungen
|
IL292449B2
(en)
|
2015-03-13 |
2024-02-01 |
Cytomx Therapeutics Inc |
Nucleic acids encoding antibodies against PDL1 and methods for their preparation
|
AU2016233143B2
(en)
|
2015-03-17 |
2021-03-25 |
Alberto Gabizon |
Methods for the treatment of bladder cancer
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
KR20170133507A
(ko)
|
2015-04-08 |
2017-12-05 |
다나-파버 캔서 인스티튜트 인크. |
인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
|
SI3283106T1
(sl)
|
2015-04-13 |
2022-04-29 |
Pfizer Inc. |
Terapevtska protitelesa in njihova uporaba
|
DK3283524T3
(da)
|
2015-04-17 |
2023-05-30 |
Amgen Res Munich Gmbh |
BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
|
KR20170138556A
(ko)
|
2015-05-01 |
2017-12-15 |
다나-파버 캔서 인스티튜트 인크. |
항ccr4 항체를 이용하여 사이토카인 발현을 매개하는 방법
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
AU2016257929B2
(en)
|
2015-05-04 |
2022-10-20 |
Cytomx Therapeutics, Inc |
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
|
CA3176004A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3294887A1
(de)
|
2015-05-14 |
2018-03-21 |
CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
Mirna-zusammensetzungen zur behandlung von neoplasmen reifer b-zellen
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
US10849917B2
(en)
|
2015-06-01 |
2020-12-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type VII collagen
|
JP2018517774A
(ja)
|
2015-06-10 |
2018-07-05 |
エリジウム・ヘルス・インコーポレイテッド |
ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
|
CA2991167A1
(en)
|
2015-07-02 |
2017-01-05 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
KR20180040138A
(ko)
|
2015-07-13 |
2018-04-19 |
싸이톰스 테라퓨틱스, 인크. |
항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
|
US20180305451A1
(en)
|
2015-07-13 |
2018-10-25 |
Compugen Ltd. |
Hide1 compositions and methods
|
JP2018520683A
(ja)
|
2015-07-17 |
2018-08-02 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
多標的単一体コンジュゲート
|
US10913802B2
(en)
|
2015-07-21 |
2021-02-09 |
Dyax Corp. |
Monoclonal antibody inhibitor of factor XIIA
|
ES2828694T3
(es)
|
2015-07-29 |
2021-05-27 |
Allergan Inc |
Anticuerpos sólo de cadena pesada frente a ANG-2
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
US10308711B2
(en)
|
2015-08-14 |
2019-06-04 |
Allergan, Inc. |
Heavy chain only antibodies to PDGF
|
SI3337467T1
(sl)
|
2015-08-20 |
2021-03-31 |
Ipsen Biopharm Ltd. Ash Road |
Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
|
EP3791876A1
(de)
|
2015-08-21 |
2021-03-17 |
Ipsen Biopharm Ltd. |
Verfahren zur behandlung von metastasierendem bauchspeicheldrüsenkrebs mithilfe von kombinationstherapien mt liposomalem irinotecan und oxaliplatin
|
WO2017040566A1
(en)
|
2015-09-01 |
2017-03-09 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of lupus nephritis
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
RS62330B1
(sr)
|
2015-09-15 |
2021-10-29 |
Scholar Rock Inc |
Antitela pro/latentnog miostatina i njihova upotreba
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
EP3359572A2
(de)
|
2015-10-06 |
2018-08-15 |
H. Hoffnabb-La Roche Ag |
Verfahren zur behandlung von multipler sklerose
|
EP3858993A1
(de)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
|
GB201518172D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
GB201518170D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
|
GB201518171D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for topical administration with therapeutic agent
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
CN108366965B
(zh)
|
2015-10-16 |
2021-10-01 |
易普森生物制药有限公司 |
稳定喜树碱药物组合物
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
EP3370734B1
(de)
|
2015-11-05 |
2023-01-04 |
Children's Hospital Los Angeles |
Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
|
WO2017079563A1
(en)
|
2015-11-06 |
2017-05-11 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
WO2017083403A1
(en)
|
2015-11-10 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Echinomycin formulation, method of making and method of use thereof
|
CN114469872A
(zh)
|
2015-11-12 |
2022-05-13 |
灰色视觉公司 |
用于治疗的聚集性微粒
|
KR20180088381A
(ko)
|
2015-11-12 |
2018-08-03 |
시아맙 쎄라퓨틱스, 인코포레이티드 |
글리칸-상호작용 화합물 및 사용방법
|
US20170216452A1
(en)
|
2015-11-30 |
2017-08-03 |
Pfizer Inc. |
Antibodies and antibody fragments for site-specific conjugation
|
TWI726942B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
JP7090545B2
(ja)
|
2015-12-02 |
2022-06-24 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
MA43415A
(fr)
|
2015-12-09 |
2018-10-17 |
Modernatx Inc |
Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
|
WO2017105990A1
(en)
|
2015-12-14 |
2017-06-22 |
Massachusetts Institute Of Technology |
Ph-responsive mucoadhesive polymeric encapsulated microorganisms
|
EP3389720A1
(de)
|
2015-12-18 |
2018-10-24 |
The General Hospital Corporation |
Polyacetalpolymere, konjugate, partikel und verwendungen davon
|
EP3395370B1
(de)
|
2015-12-21 |
2021-01-20 |
FUJIFILM Corporation |
Liposom und liposomzusammensetzung
|
WO2017117218A1
(en)
|
2015-12-30 |
2017-07-06 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
AU2017206069A1
(en)
|
2016-01-08 |
2018-07-19 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
EP3405579A1
(de)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Boten-ribonukleinsäuren (mrna) zur herstellung intrazellulärer bindungspolypeptide und verfahren zur verwendung davon
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
KR20180103084A
(ko)
|
2016-02-03 |
2018-09-18 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
MX2018009386A
(es)
|
2016-02-03 |
2018-11-09 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecificos para psma y cd3 que se ligan a celulas t.
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
EP3426306A1
(de)
*
|
2016-03-07 |
2019-01-16 |
Memorial Sloan Kettering Cancer Center |
Knochenmark-, retikuloendotheliale system- und/oder lymphknoten-gerichtete radioaktiv markierte liposomen sowie verfahren zu deren diagnostischen und therapeutischen verwendung
|
EP4169942A1
(de)
|
2016-03-11 |
2023-04-26 |
Scholar Rock, Inc. |
Tgfbeta1-bindende immunglobuline und verwendung davon
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
US10973748B2
(en)
|
2016-04-21 |
2021-04-13 |
Versitech Limited |
Compositions and methods for lightening skin and reducing hyperpigmentation
|
ES2963807T3
(es)
|
2016-06-08 |
2024-04-02 |
Xencor Inc |
Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
|
ITUA20164630A1
(it)
|
2016-06-23 |
2017-12-23 |
Paolo Blasi |
Adiuvanti farmacologici per la termoablazione tumorale
|
EP3474886B1
(de)
|
2016-06-27 |
2021-08-04 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung von hypophosphatasie bei kindern und jugendlichen
|
WO2018005657A1
(en)
|
2016-06-28 |
2018-01-04 |
Verily Life Sciences Llc |
Serial filtration to generate small cholesterol-containing liposomes
|
IL296127A
(en)
|
2016-07-22 |
2022-11-01 |
Dana Farber Cancer Inst Inc |
Antibodies to the glucocorticoid-induced tumor necrosis factor receptor and methods of using them
|
CN109862896A
(zh)
|
2016-08-03 |
2019-06-07 |
西玛贝医药公司 |
用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
|
TWI754659B
(zh)
|
2016-08-08 |
2022-02-11 |
台灣微脂體股份有限公司 |
用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
EP3509633A1
(de)
|
2016-09-06 |
2019-07-17 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur behandlung oder vorbeugung einer zika-virus-infektion
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
CA3036829A1
(en)
|
2016-09-14 |
2018-03-22 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
KR20190067181A
(ko)
|
2016-09-23 |
2019-06-14 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
군발성 두통의 치료
|
BR112019005823A2
(pt)
|
2016-09-23 |
2019-06-25 |
Teva Pharmaceuticals Int Gmbh |
tratamento para enxaqueca refratária
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
MX2019004783A
(es)
|
2016-11-02 |
2019-08-12 |
Ipsen Biopharm Ltd |
Tratamiento de cancer gastrico usando terapias de combinacion que comprenden irinotecan liposomico oxaliplatino, 5-fluoruracilo (y leucovorina).
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
AU2017353936A1
(en)
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
EP3538546A1
(de)
|
2016-11-14 |
2019-09-18 |
Novartis AG |
Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion
|
EP3541847A4
(de)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
US10772926B2
(en)
|
2016-12-16 |
2020-09-15 |
Nutragen Health Innovations, Inc. |
Natural drugs for the treatment of inflammation and melanoma
|
MY195385A
(en)
|
2016-12-16 |
2023-01-18 |
Pfizer |
Glp-1 Receptor Agonists And Uses Thereof
|
AU2018205231A1
(en)
|
2017-01-06 |
2019-07-18 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
|
HRP20230308T1
(hr)
|
2017-01-06 |
2023-05-12 |
Scholar Rock, Inc. |
Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
MX2019009070A
(es)
|
2017-02-01 |
2019-10-30 |
Modernatx Inc |
Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
JP2020510435A
(ja)
|
2017-03-03 |
2020-04-09 |
ライナット ニューロサイエンス コーポレイション |
抗gitr抗体およびその使用方法
|
CA3055574A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
WO2018183173A1
(en)
|
2017-03-27 |
2018-10-04 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
WO2018191153A1
(en)
|
2017-04-09 |
2018-10-18 |
The Cleveland Clinic Foundation |
Cancer treatment by malat1 inhibition
|
JP2020512825A
(ja)
|
2017-04-12 |
2020-04-30 |
ファイザー・インク |
条件的親和性を有する抗体およびその使用の方法
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
US11866506B2
(en)
|
2017-04-21 |
2024-01-09 |
Mellitus, Llc |
Anti-CD59 antibodies
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
US11160870B2
(en)
|
2017-05-10 |
2021-11-02 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
EP3622074A4
(de)
|
2017-05-12 |
2021-01-13 |
Augusta University Research Institute, Inc. |
Menschliche alpha-fetoprotein-spezifische t-zellrezeptoren und ihre verwendung
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
US11260117B2
(en)
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
AU2018278327B2
(en)
|
2017-06-01 |
2023-03-16 |
Cytomx Therapeutics, Inc. |
Activatable anti-pdl1 antibodies and methods of use thereof
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
PE20200746A1
(es)
|
2017-07-06 |
2020-07-24 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE iARN PARA LA INHIBICION DE LA EXPRESION DE ALFA-ENAC Y METODOS DE USO
|
EP3651799A1
(de)
|
2017-07-13 |
2020-05-20 |
Massachusetts Institute of Technology |
Targeting des hdac2-sp3-komplexes zur verbesserung der synaptischen funktion
|
WO2019014586A1
(en)
|
2017-07-14 |
2019-01-17 |
Cytomx Therapeutics, Inc. |
ANTI-CD166 ANTIBODIES AND USES THEREOF
|
EP3655430A1
(de)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
|
WO2019018828A1
(en)
|
2017-07-20 |
2019-01-24 |
Cytomx Therapeutics, Inc. |
METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
WO2019018765A1
(en)
|
2017-07-21 |
2019-01-24 |
Modernatx, Inc. |
MODIFIED mRNA ENCODING PROPIONYL-COA-CARBOXYLASE AND USES THEREOF
|
MA49684A
(fr)
|
2017-07-24 |
2020-06-03 |
Modernatx Inc |
Arnm modifié codant une glucose-6-phosphatase et utilisations associées
|
EP3658184B1
(de)
|
2017-07-27 |
2023-09-06 |
Alexion Pharmaceuticals, Inc. |
Hochkonzentrierte anti-c5-antikörperformulierungen
|
CA3071427A1
(en)
|
2017-07-28 |
2019-01-31 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
MX2020001233A
(es)
|
2017-08-03 |
2020-07-20 |
Otsuka Pharma Co Ltd |
Compuesto farmaceutico y metodos de purificacion del mismo.
|
US11135187B2
(en)
|
2017-08-22 |
2021-10-05 |
National Institutes Of Health (Nih) |
Compositions and methods for treating diabetic retinopathy
|
BR112020004231A2
(pt)
|
2017-08-30 |
2020-09-08 |
Cytomx Therapeutics, Inc. |
anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
KR20200045520A
(ko)
|
2017-09-07 |
2020-05-04 |
오거스타 유니버시티 리서치 인스티튜트, 인크. |
프로그래밍된 세포사 단백질 1에 대한 항체
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
CA3078974A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
SG11202002384VA
(en)
|
2017-10-14 |
2020-04-29 |
Cytomx Therapeutics Inc |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
EA202090681A1
(ru)
|
2017-10-17 |
2020-07-21 |
Ризен Фармасьютикалз Са |
Модуляторы каналов crac для лечения рака пищевода
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
WO2019082124A1
(en)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
|
CA3079788C
(en)
|
2017-10-27 |
2023-09-05 |
Pfizer Inc. |
Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
|
SG11202003437PA
(en)
|
2017-10-30 |
2020-05-28 |
Rhizen Pharmaceuticals Sa |
Calcium release-activated calcium channel modulators for treating hematological and solid cancers
|
WO2019086626A1
(en)
|
2017-11-03 |
2019-05-09 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS
|
JP2021505571A
(ja)
|
2017-12-06 |
2021-02-18 |
ルヒゼン ファーマスティカルズ エスエー |
末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
EP3724229A1
(de)
|
2017-12-11 |
2020-10-21 |
Amgen Inc. |
Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
WO2019165101A1
(en)
|
2018-02-22 |
2019-08-29 |
Verily Life Sciences Llc |
Combining orthogonal chemistries for preparation of multiplexed nanoparticles
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
EP3762420A1
(de)
|
2018-03-09 |
2021-01-13 |
CytomX Therapeutics, Inc. |
Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
|
US11203646B2
(en)
|
2018-03-14 |
2021-12-21 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
US11485782B2
(en)
|
2018-03-14 |
2022-11-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
WO2019183320A1
(en)
|
2018-03-21 |
2019-09-26 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
US10722528B2
(en)
|
2018-03-28 |
2020-07-28 |
Augusta University Research Institute, Inc. |
Compositions and methods for inhibiting metastasis
|
JP2021520781A
(ja)
|
2018-04-06 |
2021-08-26 |
チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation |
体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
US20210115156A1
(en)
|
2018-04-13 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
EP3788071A1
(de)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
WO2019224715A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
WO2019234680A1
(en)
|
2018-06-08 |
2019-12-12 |
Pfizer Inc. |
Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone
|
TWI707683B
(zh)
|
2018-06-13 |
2020-10-21 |
美商輝瑞股份有限公司 |
Glp-1受體促效劑及其用途
|
HUE061888T2
(hu)
|
2018-06-15 |
2023-08-28 |
Pfizer |
GLP-1 receptor agonisták és alkalmazásaik
|
US20210347842A1
(en)
|
2018-06-19 |
2021-11-11 |
Eli Lilly And Company |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
KR20210027389A
(ko)
|
2018-06-28 |
2021-03-10 |
크리스퍼 테라퓨틱스 아게 |
공여자 폴리뉴클레오티드의 삽입에 의한 게놈 편집을 위한 조성물 및 방법
|
AU2019291890A1
(en)
|
2018-06-29 |
2020-12-17 |
Boehringer Ingelheim International Gmbh |
Anti-CD40 antibodies for use in treating autoimmune disease
|
EP3817810A1
(de)
|
2018-07-06 |
2021-05-12 |
Pfizer Inc. |
Herstellungsverfahren und zwischenprodukte für eine pyrrolo- [2,3- d] pyrimidinverbindung und deren verwendung
|
PL3677278T3
(pl)
|
2018-07-11 |
2022-02-28 |
Scholar Rock, Inc. |
Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
|
KR20210058811A
(ko)
|
2018-07-11 |
2021-05-24 |
스칼러 락, 인크. |
고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
|
WO2020014473A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
TGFβ1 INHIBITORS AND USE THEREOF
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
WO2020037125A1
(en)
|
2018-08-16 |
2020-02-20 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US20220023450A1
(en)
*
|
2018-09-11 |
2022-01-27 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
US20210338728A1
(en)
|
2018-09-27 |
2021-11-04 |
Phosphogam, Inc. |
Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
|
CA3114567A1
(en)
|
2018-09-28 |
2020-04-02 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
|
MA53859A
(fr)
|
2018-10-10 |
2022-01-19 |
Boehringer Ingelheim Int |
Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
|
CA3114802A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020079652A1
(en)
|
2018-10-17 |
2020-04-23 |
Insilico Medicine Hong Kong Limited |
Kinase inhibitors
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
WO2020087064A2
(en)
*
|
2018-10-26 |
2020-04-30 |
University Of Connecticut |
A continuous processing system and methods for internal and external modifications to nanoparticles
|
KR20210098989A
(ko)
|
2018-11-02 |
2021-08-11 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 항-cd166 항체 및 이의 사용 방법
|
MX2021006034A
(es)
|
2018-11-22 |
2021-09-21 |
Qilu Regor Therapeutics Inc |
Agonistas de glp-ir y usos de los mismos.
|
WO2020113135A1
(en)
|
2018-11-29 |
2020-06-04 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
US20200377602A1
(en)
|
2018-12-06 |
2020-12-03 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
CA3122762A1
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
US20220090021A1
(en)
|
2019-01-22 |
2022-03-24 |
Massachusetts Institute Of Technology |
In vitro human blood brain barrier
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
SG11202108099WA
(en)
|
2019-01-30 |
2021-08-30 |
Scholar Rock Inc |
LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
|
CN113646310A
(zh)
|
2019-02-15 |
2021-11-12 |
辉瑞公司 |
结晶性的嘧啶基-3,8-二氮杂双环[3.2.1]辛烷基甲酮化合物及其用途
|
WO2020170103A1
(en)
|
2019-02-18 |
2020-08-27 |
Pfizer Inc. |
Method of treatment of chronic low back pain
|
US20220275059A1
(en)
|
2019-02-20 |
2022-09-01 |
Harbour Antibodies Bv |
Antibodies
|
US11739078B2
(en)
|
2019-02-22 |
2023-08-29 |
Insilico Medicine Ip Limited |
Methods of inhibiting kinases
|
CN113677372A
(zh)
|
2019-02-26 |
2021-11-19 |
西托姆克斯治疗公司 |
可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
|
WO2020181058A1
(en)
|
2019-03-05 |
2020-09-10 |
Massachusetts Institute Of Technology |
Dna launched rna replicon system (drep) and uses thereof
|
SG11202109514VA
(en)
|
2019-03-08 |
2021-09-29 |
Massachusetts Inst Technology |
Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
CN113660953A
(zh)
|
2019-04-01 |
2021-11-16 |
豪夫迈·罗氏有限公司 |
用于稳定含蛋白质制剂的组合物和方法
|
JP7284830B2
(ja)
|
2019-04-02 |
2023-05-31 |
アレイ バイオファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ阻害剤
|
US20220363673A1
(en)
|
2019-06-28 |
2022-11-17 |
Pfizer Inc. |
5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
LT6699B
(lt)
|
2019-07-15 |
2020-02-10 |
UAB "Valentis" |
Proliposomų gamybos būdas, naudojant ne daugiau kaip 5 % etanolio, ir jų panaudojimas lipofilinių medžiagų kapsuliavimui
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
US10758329B1
(en)
|
2019-08-20 |
2020-09-01 |
Raymond L. Wright, III |
Hydrating mouth guard
|
WO2021046122A1
(en)
|
2019-09-03 |
2021-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP4034171A1
(de)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anti-cd47-antikörper, aktivierbare anti-cd47-antikörper und verfahren zur verwendung davon
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
WO2021062092A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Trans-activated functional rna by strand displacement and uses thereof
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
WO2021071830A1
(en)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
EP4048251A1
(de)
|
2019-10-21 |
2022-08-31 |
Rhizen Pharmaceuticals AG |
Zusammensetzungen, die einen dhodh-inhibitor umfassen, zur behandlung von akuter myeloischer leukämie
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
KR20220112811A
(ko)
|
2019-12-10 |
2022-08-11 |
화이자 인코포레이티드 |
2-((4-((S)-2-(5-클로로피리딘-2-일)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((S)-옥세탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카르복실산, 1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
|
US20230057012A1
(en)
|
2020-01-11 |
2023-02-23 |
Scholar Rock, Inc. |
Tgfb inhibitors and use thereof
|
US20230050148A1
(en)
|
2020-01-11 |
2023-02-16 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
WO2021151079A1
(en)
|
2020-01-24 |
2021-07-29 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
EP4103714A1
(de)
|
2020-02-10 |
2022-12-21 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der vegf-a expression
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
CA3170563A1
(en)
|
2020-03-06 |
2021-09-10 |
Raymond P. Goodrich |
Production of vaccines comprising inactivated sars-cov-2 viral particles
|
JP2023517044A
(ja)
|
2020-03-09 |
2023-04-21 |
ファイザー・インク |
融合タンパク質およびその使用
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
US20230095383A1
(en)
|
2020-03-17 |
2023-03-30 |
Dst Pharma, Inc. |
Methods and compositions for treating viral infections
|
EP4125820A4
(de)
|
2020-03-26 |
2024-04-10 |
Plx Opco Inc |
Pharmazeutische träger mit fähigkeit zur ph-abhängigen rekonstitution und verfahren zur herstellung und verwendung davon
|
WO2021191812A1
(en)
|
2020-03-27 |
2021-09-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
JP2023520582A
(ja)
|
2020-04-06 |
2023-05-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Myoc発現をサイレンシングするための組成物および方法
|
US20230159933A1
(en)
|
2020-04-07 |
2023-05-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021205322A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
|
MX2022013176A
(es)
|
2020-04-24 |
2022-11-30 |
Millennium Pharm Inc |
Anticuerpos anti cumulo de diferenciacion 19 (cd19) y sus usos.
|
US20230181750A1
(en)
|
2020-05-06 |
2023-06-15 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
US20210355463A1
(en)
|
2020-05-15 |
2021-11-18 |
Crispr Therapeutics Ag |
Messenger rna encoding cas9 for use in genome-editing systems
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
AU2021281237A1
(en)
|
2020-05-27 |
2023-01-19 |
Qilu Regor Therapeutics Inc. |
Salt and crystal forms of GLP-1R agonists and uses thereof
|
BR112022024527A2
(pt)
|
2020-06-09 |
2022-12-27 |
Pfizer |
Compostos de espiro como antagonistas do receptor de melanocortina 4 e usos dos mesmos
|
MX2022016590A
(es)
|
2020-06-26 |
2023-02-01 |
Pfizer |
Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
EP4182346A1
(de)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutische antikörper und deren verwendungen
|
EP4185274A1
(de)
|
2020-07-24 |
2023-05-31 |
Strand Therapeutics Inc. |
Lipidnanopartikel mit modifizierten nukleotiden
|
IL300110A
(en)
|
2020-07-28 |
2023-03-01 |
Jazz Pharmaceuticals Ireland Ltd |
Chiral synthesis of RAF inhibitors in compressed cyclics
|
BR112023001557A2
(pt)
|
2020-07-28 |
2023-04-04 |
Jazz Pharmaceuticals Ireland Ltd |
Inibidores de raf bicíclicos fundidos e métodos para uso dos mesmos
|
MX2023001490A
(es)
|
2020-08-05 |
2023-04-27 |
Synthekine Inc |
Moleculas de union a il27r\03b1 y metodos de uso.
|
WO2022032006A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
AU2021320233A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL10Ra binding molecules and methods of use
|
EP4192877A1
(de)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Synthetische il2rb/il2rg-zytokine
|
AR123156A1
(es)
|
2020-08-06 |
2022-11-02 |
Qilu Regor Therapeutics Inc |
Agonistas de glp-1r y sus usos
|
JP2023538012A
(ja)
|
2020-08-14 |
2023-09-06 |
カイト ファーマ インコーポレイテッド |
免疫細胞機能の改善
|
KR20230069961A
(ko)
|
2020-09-14 |
2023-05-19 |
보르 바이오파마 인크. |
Cd33에 대한 단일 도메인 항체
|
US20220089759A1
(en)
|
2020-09-21 |
2022-03-24 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
KR20230104152A
(ko)
|
2020-10-06 |
2023-07-07 |
젠코어 인코포레이티드 |
전신 홍반성 루푸스(sle)를 포함하는 자가면역 질환을 치료하기 위한 바이오마커, 방법 및 조성물
|
CN116710446A
(zh)
|
2020-10-14 |
2023-09-05 |
上海齐鲁锐格医药研发有限公司 |
Glp-1r激动剂的晶型及其用途
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
US11058637B1
(en)
*
|
2020-11-25 |
2021-07-13 |
King Abdulaziz University |
Surface-modified emulsomes for intranasal delivery of drugs
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
JP2024505790A
(ja)
|
2020-12-18 |
2024-02-08 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
インテグリンアルファ11ベータ1に対する抗体
|
CN116917309A
(zh)
|
2021-01-08 |
2023-10-20 |
斯特兰德生物科技公司 |
表达构建体及其用途
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
EP4288457A2
(de)
|
2021-02-05 |
2023-12-13 |
Boehringer Ingelheim International GmbH |
Anti-il1rap-antikörper
|
US11530197B2
(en)
|
2021-02-24 |
2022-12-20 |
Insilico Medicine Ip Limited |
Analogs for the treatment of disease
|
EP4305053A1
(de)
|
2021-03-11 |
2024-01-17 |
Kite Pharma, Inc. |
Verbesserung der immunzellenfunktion
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
JP2024512574A
(ja)
|
2021-03-22 |
2024-03-19 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
JP2024511137A
(ja)
|
2021-03-22 |
2024-03-12 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
JP2024515066A
(ja)
|
2021-04-09 |
2024-04-04 |
武田薬品工業株式会社 |
補体因子dを標的とする抗体及びその使用
|
JP2024516168A
(ja)
|
2021-04-22 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
がんを治療するための組成物および方法
|
US20230018888A1
(en)
|
2021-04-26 |
2023-01-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
US20230111279A1
(en)
|
2021-04-26 |
2023-04-13 |
Millennium Pharmaceuticals, Inc. |
Anti-clec12a antibodies and uses thereof
|
EP4334354A1
(de)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen alk und verfahren zur verwendung davon
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
AU2022299185A1
(en)
|
2021-06-23 |
2024-01-25 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
TW202306985A
(zh)
|
2021-07-12 |
2023-02-16 |
美商建南德克公司 |
降低抗體-脂酶結合之結構
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
GB202111757D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
GB202111759D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles
|
GB202111758D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
AU2022336407A1
(en)
|
2021-08-31 |
2024-02-22 |
Pfizer Inc. |
Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
WO2023034901A1
(en)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Tumor avatar vaccine compositions and uses thereof
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
TW202337429A
(zh)
|
2021-12-01 |
2023-10-01 |
美商輝瑞股份有限公司 |
支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2023105371A1
(en)
|
2021-12-08 |
2023-06-15 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111817A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212618A1
(en)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023228023A1
(en)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2023235852A1
(en)
|
2022-06-03 |
2023-12-07 |
Zenas Biopharma, Inc. |
Methods and compositions for treating igg4- related diseases
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|